var docs;if (!docs) docs =[]; docs["78"]={"7800":"<p><b>Title</b> Dolutegravir / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase the dolutegravir dose to 50 mg twice daily in adult or pediatric patients receiving efavirenz. Consider alternatives to efavirenz when possible for integrase strand transfer inhibitor (INSTI) experienced patients with clinically suspected INSTI resistance or when certain INSTI associated resistance substitutions are present (see the full dolutegravir drug monograph or dolutegravir prescribing information for details).</p> \n<p><b>Discussion</b> In a clinical study summarized in dolutegravir U.S. prescribing information, coadministration of efavirenz (600 mg daily) decreased the dolutegravir (50 mg daily) maximum concentration, minimum concentration, and AUC by 39%, 75%, and 57%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is efavirenz induction of UGT1A1 and CYP3A mediated dolutegravir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare, August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7801":"<p><b>Title</b> Dolutegravir / Fosamprenavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: This interaction applies specifically to the use of fosamprenavir/ritonavir with dolutegravir. The impact of fosamprenavir alone on dolutegravir exposure is unknown.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosamprenavir may decrease the serum concentration of Dolutegravir. Specifically, Fosamprenavir/Ritonavir may decrease the serum concentration of Dolutegravir. The individual contributions of Fosamprenavir and Ritonavir to this effect are unknown. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase the dolutegravir dose to 50 mg twice daily in adult or pediatric patients (who are at least 12 years of age and who weigh at least 40 kg) receiving fosamprenavir/ritonavir. Consider alternatives to fosamprenavir/ritonavir when possible for integrase strand transfer inhibitor (INSTI) experienced patients with clinically suspected INSTI resistance or when certain INSTI associated resistance substitutions are present (see the full dolutegravir drug monograph or dolutegravir prescribing information for details).</p> \n<p><b>Discussion</b> In a clinical study summarized in dolutegravir U.S. prescribing information, coadministration of fosamprenavir/ritonavir (700/100 mg twice daily) decreased the dolutegravir (50 mg daily) maximum concentration, minimum concentration, and AUC by 24%, 49%, and 35%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is fosamprenavir/ritonavir induction of UGT1A1 and CYP3A mediated dolutegravir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare, August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7802":"<p><b>Title</b> Dolutegravir / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tipranavir may decrease the serum concentration of Dolutegravir. Specifically, Tipranavir/Ritonavir may decrease the serum concentration of Dolutegravir. The individual contributions of Tipranavir and Ritonavir to this effect are unknown. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase the dolutegravir dose to 50 mg twice daily in adult or pediatric patients receiving tipranavir/ritonavir. Consider alternatives to tipranavir/ritonavir when possible for integrase strand transfer inhibitor (INSTI) experienced patients with clinically suspected INSTI resistance or when certain INSTI associated resistance substitutions are present (see the full dolutegravir drug monograph or dolutegravir prescribing information for details).</p> \n<p><b>Discussion</b> In a clinical study summarized in dolutegravir U.S. prescribing information, coadministration of tipranavir/ritonavir (500/200 mg twice daily) decreased the dolutegravir (50 mg daily) maximum concentration, minimum concentration, and AUC by 46%, 76%, and 59%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is tipranavir/ritonavir induction of UGT1A1 and CYP3A mediated dolutegravir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare, August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7803":"<p><b>Title</b> Dolutegravir / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase the dolutegravir dose to 50 mg twice daily in adult or pediatric patients receiving rifampin. Consider alternatives to rifampin when possible for integrase strand transfer inhibitor (INSTI) experienced patients with clinically suspected INSTI resistance or when certain INSTI associated resistance substitutions are present (see the full dolutegravir drug monograph or dolutegravir prescribing information for details).</p> \n<p><b>Discussion</b> In a clinical study summarized in dolutegravir U.S. prescribing information, coadministration of rifampin (600 mg daily) decreased dolutegravir (50 mg twice daily) maximum concentration (Cmax), minimum concentration (Cmin), and AUC by 43%, 72%, and 54%, respectively.<sup>1</sup> The estimated Cmax, Cmin, and AUC with rifampin coadministration were only 18%, 22%, and 33% higher, respectively, than those seen with dolutegravir 50 mg/day when given alone. The suspected primary mechanism of this interaction is rifampin induction of UGT1A1 and CYP3A mediated dolutegravir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare, August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7804":"<p><b>Title</b> Dolutegravir / Etravirine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Avoidance of this drug combination is not necessary when also used with: atazanavir/ritonavir; darunavir/ritonavir; or lopinavir/ritonavir.</p></li>\n <li><p><b>International labeling</b>: The management of this interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Etravirine may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> US product labeling and clinical guidelines recommend to avoid the use of etravirine with dolutegravir unless one of the following is also used: atazanavir/ritonavir; darunavir/ritonavir; or lopinavir/ritonavir. Canadian labeling states that dolutegravir and etravirine can be combined in the absence of a boosted protease inhibitor as long as the dose of dolutegravir is increased to 50 mg twice daily.</p> \n<p><b>Discussion</b> In a clinical study summarized in dolutegravir and etravirine US prescribing information, coadministration of etravirine (200 mg twice daily) decreased the dolutegravir (50 mg daily) maximum concentration (Cmax), minimum concentration (Cmin), and AUC by 52%, 88%, and 71%, respectively.<sup>1,2</sup> In contrast, the use of etravirine (200 mg twice daily) with darunavir/ritonavir (600/100 mg twice daily) decreased the dolutegravir Cmax, Cmin, and AUC by only 12%, 37%, and 25%, respectively, and the use of etravirine (200 mg twice daily) with lopinavir/ritonavir (400/100 mg twice daily) increased these variables by7%, 28%, and 11%, respectively. <br><br>Etravirine and dolutegravir US prescribing information and clinical guidelines recommend that dolutegravir be combined with etravirine only when also combined with darunavir/ritonavir, lopinavir/ritonavir, or atazanavir/ritonavir.<sup>1,2,3</sup> In contrast, the Canadian product monograph for dolutegravir suggests increasing the dolutegravir dose to 50 mg twice daily if combined with etravirine in the absence of a boosted protease inhibitor.<sup>4</sup><br><br>The suspected primary mechanism of this interaction is etravirine induction of dolutegravir metabolism (likely via UGT1A1 and/or CYP3A). The coadministration of darunavir/ritonavir or lopinavir/ritonavir appears to diminish this effect (atazanavir/ritonavir is predicted to do the same), likely via inhibition of CYP3A function and possibly UGT1A1 as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; December 2014.</p>\n<p>2. Intelence (etravirine) [prescribing information]. Titusville, NJ: Janssen Products LP; August 2014.</p>\n<p>3. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Published April 2015. Accessed July 22, 2015.</p>\n<p>4. Tivicay (dolutegravir) [product monograph]. Laval, Quebec, Canada: ViiV Healthcare ULC; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7805":"<p><b>Title</b> Dofetilide / Dolutegravir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dolutegravir may increase the serum concentration of Dofetilide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of dofetilide with dolutegravir, due to the potential for increased dofetilide plasma concentrations and toxic effects. This combination is listed as contraindicated by dolutegravir U.S. prescribing information.</p> \n<p><b>Discussion</b> Dolutegravir U.S. prescribing information lists its concomitant use with dofetilide as contraindicated due to the potential for dolutegravir to increase dofetilide plasma concentrations via inhibition of its OCT2 mediated active renal tubular secretion.<sup>1</sup> This interaction has not been investigated in humans, although dolutegravir does inhibit OCT2 mediated secretion of creatinine in humans.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare, August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7806":"<p><b>Title</b> MetFORMIN / Dolutegravir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dolutegravir may increase the serum concentration of MetFORMIN. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit the daily metformin dose to 1,000 mg when used with dolutegravir. Monitor for increased metformin effects/toxicities during concomitant use.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of healthy volunteers, the metformin (500 mg twice daily) AUC increased 1.8-fold when combined with dolutegravir 50 mg once daily (n=14) and increased and 2.5-fold when combined with dolutegravir 50 mg twice daily (n=13).<sup>1,2</sup><br><br>In a retrospective analysis of 15 patients on stable doses of metformin who initiated dolutegravir (50 mg daily), there no change in fasting glucose concentrations or HgA1C levels.<sup>3</sup> No cases of lactic acidosis or hypoglycemia were identified.<sup>3</sup><br><br>Dolutegravir prescribing information states that because dolutegravir has been shown to inhibit both the organic cation transporter 2 (OCT2) and the multidrug and toxin extrusion protein 1 (MATE1), plasma concentrations of drugs eliminated by the OCT2 or MATE1 transporters, such as metformin, may increase with concurrent use of transport inhibitors such as dolutegravir.<sup>4</sup> Increased monitoring and metformin dose limits are recommended.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zong J, Borland J, Jerva F, Wynne B, Choukour M, Song I. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. <i>J Int AIDS Soc</i>. 2014;17(4 suppl 3):19584. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25394090\">[PubMed 25394090]</a></p>\n<p>2. Song IH, Zong J, Borland J, et al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. <i>J Acquir Immune Defic Syndr</i>. 2016;72(4):400-407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26974526\">[PubMed 26974526]</a></p>\n<p>3. Gervasoni C, Minisci D, Clementi E, Rizzardini G, Cattaneo D. How relevant is the interaction between dolutegravir and metformin in real life? <i>J Acquir Immune Defic Syndr</i>. 2017;75(1):e24-e26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28114188\">[PubMed 28114188]</a></p>\n<p>4. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7807":"<p><b>Title</b> Dolutegravir / OXcarbazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The management of this potential interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> OXcarbazepine may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> US labeling states that the concomitant use of dolutegravir and oxcarbazepine should be avoided. Canadian labeling states that dolutegravir and oxcarbazepine can be combined as long as it is used in patients without integrase strand transfer inhibitor resistance and the dolutegravir dose is increased to 50 mg twice daily.</p> \n<p><b>Discussion</b> Dolutegravir US prescribing information recommends avoiding the concomitant use of dolutegravir and certain enzyme-inducing medications due to the unknown capacity for these agents to decrease dolutegravir exposure (eg, via induction of its metabolism by UGT1A1 and/or CYP3A).<sup>1</sup> Specific agents listed as potentially interacting include: carbamazepine; nevirapine; oxcarbazepine; phenobarbital; phenytoin; and St. John's wort. Canadian labeling for dolutegravir states that these agents should not be combined with dolutegravir in patients with integrase strand transfer inhibitor resistant HIV strains, but could be used in other patients as long as the dolutegravir dose is increased to 50 mg twice daily.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</p>\n<p>2. Tivicay (dolutegravir) [product monograph]. Laval, Quebec, Canada: ViiV Healthcare ULC; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7808":"<p><b>Title</b> Dolutegravir / Fosphenytoin-Phenytoin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The management of this potential interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> US labeling states that the concomitant use of dolutegravir and phenytoin should be avoided. Canadian labeling states that dolutegravir and phenytoin can be combined as long as it is used in patients without integrase strand transfer inhibitor resistance and the dolutegravir dose is increased to 50 mg twice daily.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Dolutegravir US prescribing information recommends avoiding the concomitant use of dolutegravir and certain enzyme-inducing medications due to the unknown capacity for these agents to decrease dolutegravir exposure (eg, via induction of its metabolism by UGT1A1 and/or CYP3A).<sup>1</sup> Specific agents listed as potentially interacting include: carbamazepine; nevirapine; oxcarbazepine; phenobarbital; phenytoin; and St. John's wort. Canadian labeling for dolutegravir states that these agents should not be combined with dolutegravir in patients with integrase strand transfer inhibitor resistant HIV strains, but could be used in other patients as long as the dolutegravir dose is increased to 50 mg twice daily.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</p>\n<p>2. Tivicay (dolutegravir) [product monograph]. Laval, Quebec, Canada: ViiV Healthcare ULC; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7809":"<p><b>Title</b> Dolutegravir / PHENobarbital</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The management of this potential interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> US labeling states that the concomitant use of dolutegravir and phenobarbital should be avoided. Canadian labeling states that dolutegravir and phenobarbital can be combined as long as it is used in patients without integrase strand transfer inhibitor resistance and the dolutegravir dose is increased to 50 mg twice daily.</p> \n<p><b>Discussion</b> Dolutegravir US prescribing information recommends avoiding the concomitant use of dolutegravir and certain enzyme-inducing medications due to the unknown capacity for these agents to decrease dolutegravir exposure (eg, via induction of its metabolism by UGT1A1 and/or CYP3A).<sup>1</sup> Specific agents listed as potentially interacting include: carbamazepine; nevirapine; oxcarbazepine; phenobarbital; phenytoin; and St. John's wort. Canadian labeling for dolutegravir states that these agents should not be combined with dolutegravir in patients with integrase strand transfer inhibitor resistant HIV strains, but could be used in other patients as long as the dolutegravir dose is increased to 50 mg twice daily.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</p>\n<p>2. Tivicay (dolutegravir) [product monograph]. Laval, Quebec, Canada: ViiV Healthcare ULC; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7810":"<p><b>Title</b> Dolutegravir / Primidone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The management of this potential interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Primidone may decrease the serum concentration of Dolutegravir. Specifically, the Primidone metabolite phenobarbital may decrease Dolutegravir serum concentrations. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> US labeling states that the concomitant use of dolutegravir and phenobarbital (the major active metabolite of primidone) should be avoided. Canadian labeling states that dolutegravir and phenobarbital can be combined as long as it is used in patients without integrase strand transfer inhibitor resistance and the dolutegravir dose is increased to 50 mg twice daily.</p> \n<p><b>Discussion</b> Dolutegravir US prescribing information recommends avoiding the concomitant use of dolutegravir and certain enzyme-inducing medications due to the unknown capacity for these agents to decrease dolutegravir exposure (eg, via induction of its metabolism by UGT1A1 and/or CYP3A).<sup>1</sup> Specific agents listed as potentially interacting include: carbamazepine; nevirapine; oxcarbazepine; phenobarbital; phenytoin; and St. John's wort. Canadian labeling for dolutegravir states that these agents should not be combined with dolutegravir in patients with integrase strand transfer inhibitor resistant HIV strains, but could be used in other patients as long as the dolutegravir dose is increased to 50 mg twice daily.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</p>\n<p>2. Tivicay (dolutegravir) [product monograph]. Laval, Quebec, Canada: ViiV Healthcare ULC; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7811":"<p><b>Title</b> Dolutegravir / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> For patients who are treatment-naive or integrase strand transfer inhibitor (INSTI)-naive, increase dolutegravir dose to 50 mg twice daily when used together with carbamazepine. Patients using the combination product Triumeq (dolutegravir, abacavir, lamivudine) should accomplish this by adding an additional dolutegravir 50 mg dose separated by 12 hours from the Triumeq dose. Consider an alternative to carbamazepine when possible in patients with known or suspected INSTI resistance.</p> \n<p><b>Discussion</b> The dolutegravir AUC and minimum serum concentration were an average of 49% and 73% lower, respectively, in a study of 16 subjects who received dolutegravir 50 mg/day together with carbamazepine 300 mg twice daily.<sup>1,2</sup><br><br>The likely mechanism for this interaction is increased dolutegravir metabolism, by CYP3A4 and/or UGT1A1, by carbamazepine.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Song I, Weller S, Patel J, et al. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation. <i>Eur J Clin Pharmacol</i>. 2016; Feb 22. (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26898568\">[PubMed 26898568]</a></p>\n<p>2. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7812":"<p><b>Title</b> Dolutegravir / St John's Wort</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The management of this potential interaction differs between US and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> US labeling states that the concomitant use of dolutegravir and St. John's wort should be avoided. Canadian labeling states that dolutegravir and St. John's wort can be combined as long as it is used in patients without integrase strand transfer inhibitor resistance and the dolutegravir dose is increased to 50 mg twice daily.</p> \n<p><b>Discussion</b> Dolutegravir US prescribing information recommends avoiding the concomitant use of dolutegravir and certain enzyme-inducing medications due to the unknown capacity for these agents to decrease dolutegravir exposure (eg, via induction of its metabolism by UGT1A1 and/or CYP3A).<sup>1</sup> Specific agents listed as potentially interacting include: carbamazepine; nevirapine; oxcarbazepine; phenobarbital; phenytoin; and St. John's wort. Canadian labeling for dolutegravir states that these agents should not be combined with dolutegravir in patients with integrase strand transfer inhibitor resistant HIV strains, but could be used in other patients as long as the dolutegravir dose is increased to 50 mg twice daily.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</p>\n<p>2. Tivicay (dolutegravir) [product monograph]. Laval, Quebec, Canada: ViiV Healthcare ULC; June 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7813":"<p><b>Title</b> Dolutegravir / Nevirapine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nevirapine may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of dolutegravir with nevirapine.</p> \n<p><b>Discussion</b> Dolutegravir U.S. prescribing information recommends avoiding its use with certain enzyme-inducing medications due to the unknown capacity for these agents to decrease dolutegravir exposure (e.g., via induction of its metabolism by UGT1A1 and/or CYP3A).<sup>1</sup> Specific agents listed as potentially interacting include: carbamazepine; nevirapine; oxcarbazepine; phenobarbital; phenytoin; and St. John's wort.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare, August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7814":"<p><b>Title</b> Dolutegravir / Calcium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only anticipated with oral administration of calcium salts.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Salts may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer dolutegravir at least 2 hours before or 6 hours after oral calcium salts. If dolutegravir is administered as part of the dolutegravir/rilpivirine combination product, administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral calcium salts. Alternatively, dolutegravir and oral calcium can be taken together with food.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Chloride, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in dolutegravir US prescribing information, simultaneous administration of dolutegravir (50 mg single dose) and calcium carbonate (1,200 mg) in a fasted state decreased the dolutegravir maximum concentration (C<sub>max</sub>), minimum concentration (C<sub>min</sub>), and AUC by 47%, 49%, and 49%, respectively. When calcium carbonate was given either 2 hours after dolutegravir or simultaneously with dolutegravir but combined with food, there was no change in dolutegravir C<sub>max</sub>, C<sub>min</sub>, or AUC.<sup>1</sup> <br><br>Thus, the manufacturer recommends co-administration of dolutegravir and oral calcium salts only in the fed state or administration of dolutegravir 2 hours before or 6 hours after oral calcium salts.<sup>1</sup> Prescribing information for the dolutegravir/rilpivirie combination product recommends administration of dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral calcium salts.<sup>2</sup><br><br>The suspected primary mechanism of this interaction is binding of dolutegravir to calcium in the gastrointestinal tract to form a poorly-absorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; May 2014.</p>\n<p>2. Juluca (dolutegravir and rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7815":"<p><b>Title</b> Dolutegravir / Iron Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only anticipated with oral administration of iron salts.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Iron Salts may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer dolutegravir at least 2 hours before or 6 hours after oral iron salts. If dolutegravir is administered as part of the dolutegravir/rilpivirine combination product, administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron salts. Alternatively, dolutegravir and oral iron salts can be administered together if taken with food.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in dolutegravir US prescribing information, simultaneous administration of ferrous fumarate (324 mg) with dolutegravir (50 mg single dose) in a fasted state decreased the dolutegravir maximum concentration (C<sub>max</sub>), minimum concentration (C<sub>min</sub>), and AUC by 57%, 56%, and 54%, respectively. When ferrous fumarate was given either 2 hours after dolutegravir or simultaneously with dolutegravir but combined with food, there was no change in dolutegravir C<sub>max</sub>, C<sub>min</sub>, or AUC.<sup>1</sup> <br><br>Thus, the manufacturer recommends co-administration of dolutegravir and oral iron only in the fed state or administration of dolutegravir 2 hours before or 6 hours after oral iron salts.<sup>1</sup> Prescribing information for the dolutegravir/rilpivirie combination product recommends administration of dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron salts.<sup>2</sup><br><br><br>The suspected primary mechanism of this interaction is binding of dolutegravir to iron in the gastrointestinal tract to form a poorly-absorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; May 2014.</p>\n<p>2. Juluca (dolutegravir and rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7816":"<p><b>Title</b> Dolutegravir / Magnesium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only anticipated with oral administration of magnesium salts.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Magnesium Salts may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer dolutegravir at least 2 hours before or 6 hours after oral magnesium salts. If dolutegravir is administered as part of the dolutegravir/rilpivirine combination product, administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral magnesium salts.</p>\n<div>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate, Magnesium Trisilicate</p>\n</div> \n<p><b>Discussion</b> In clinical studies summarized in dolutegravir U.S. prescribing information, simultaneous coadministration of a magnesium oxide/aluminum oxide containing antacid with dolutegravir (50 mg single dose) decreased the dolutegravir maximum concentration (Cmax), minimum concentration (Cmin), and AUC by 72%, 74%, and 74%, respectively, while administration of the antacid 2 hours after dolutegravir decreased these variables by 18%, 30%, and 26%, respectively.<sup>1</sup> Simultaneous coadministration of an unspecified multivitamin with dolutegravir (50 mg single dose) decreased the dolutegravir Cmax, Cmin, and AUC by 35%, 32%, and 33%, respectively.<sup>1</sup> <br><br>The suspected primary mechanism of these interaction is binding of dolutegravir to cations in gastrointestinal tract to form a poorly-absorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare; August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7817":"<p><b>Title</b> Dolutegravir / Sucralfate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sucralfate may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer dolutegravir at least 2 hours before or 6 hours after sucralfate. If dolutegravir is administered as part of the dolutegravir/rilpivirine combination product, administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after sucralfate.</p> \n<p><b>Discussion</b> In clinical studies summarized in dolutegravir U.S. prescribing information, simultaneous coadministration of a magnesium oxide/aluminum oxide containing antacid with dolutegravir (50 mg single dose) decreased the dolutegravir maximum concentration (Cmax), minimum concentration (Cmin), and AUC by 72%, 74%, and 74%, respectively, while administration of the antacid 2 hours after dolutegravir decreased these variables by 18%, 30%, and 26%, respectively.<sup>1</sup> Simultaneous coadministration of an unspecified multivitamin with dolutegravir (50 mg single dose) decreased the dolutegravir Cmax, Cmin, and AUC by 35%, 32%, and 33%, respectively.<sup>1</sup> The suspected primary mechanism of these interaction is binding of dolutegravir to cations in gastrointestinal tract to form a poorly-absorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7818":"<p><b>Title</b> Dolutegravir / Aluminum Hydroxide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only anticipated with oral administration of aluminum hydroxide.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aluminum Hydroxide may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer dolutegravir at least 2 hours before or 6 hours after oral aluminum hydroxide. If dolutegravir is administered as part of the dolutegravir/rilpivirine combination product, administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral aluminum hydroxide.</p> \n<p><b>Discussion</b> In clinical studies summarized in dolutegravir U.S. prescribing information, simultaneous coadministration of a magnesium oxide/aluminum oxide containing antacid with dolutegravir (50 mg single dose) decreased the dolutegravir maximum concentration (Cmax), minimum concentration (Cmin), and AUC by 72%, 74%, and 74%, respectively, while administration of the antacid 2 hours after dolutegravir decreased these variables by 18%, 30%, and 26%, respectively.<sup>1</sup> Simultaneous coadministration of an unspecified multivitamin with dolutegravir (50 mg single dose) decreased the dolutegravir Cmax, Cmin, and AUC by 35%, 32%, and 33%, respectively.<sup>1</sup> <br><br>The suspected primary mechanism of these interaction is binding of dolutegravir to cations in gastrointestinal tract to form a poorly-absorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tivicay (dolutegravir). Research Triangle Park, NC: ViiV Healthcare, August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7819":"<p><b>Title</b> Dolutegravir / Multivitamins/Minerals (with ADEK, Folate, Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer dolutegravir at least 2 hours before or 6 hours after the dose of a multivitamin that contains polyvalent cations (e.g., calcium, iron, magnesium, selenium, zinc). If dolutegravir is administered as part of the dolutegravir/rilpivirine combination product, administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after the multivitamin. Alternatively, dolutegravir and multivitamins can be administered together if taken with food.</p> \n<p><b>Discussion</b> In a clinical study summarized in dolutegravir US prescribing information and subsequently published, simultaneous administration of a magnesium oxide/aluminum oxide containing antacid with dolutegravir (50 mg single dose) decreased the dolutegravir maximum concentration (C<sub>max</sub>), minimum concentration (C<sub>min</sub>), and AUC by 72%, 74%, and 74%, respectively, while administration of the antacid 2 hours after dolutegravir decreased these variables by 18%, 30%, and 26%, respectively.<sup>1,2</sup> Simultaneous coadministration of a high cation containing multivitamin with dolutegravir (50 mg single dose) decreased the dolutegravir Cmax, Cmin, and AUC by 35%, 32%, and 33%, respectively.<sup>1,2</sup> In a pair of clinical studies summarized in dolutegravir US prescribing information, simultaneous administration of ferrous fumarate (324 mg) or calcium carbonate (1,200 mg) with dolutegravir (50 mg single dose) in a fasted state decreased the dolutegravir C<sub>max</sub>, C<sub>min</sub>, and AUC by 47% to 57%, 49% to 56%, and 49% to 54%, respectively. When ferrous fumarate and calcium carbonate were given either 2 hours after dolutegravir or simultaneously with dolutegravir but combined with food, there was no change in dolutegravir C<sub>max</sub>, C<sub>min</sub>, or AUC.<sup>1</sup> <br><br>Thus, the manufacturer recommends co-administration of dolutegravir and multivitamins that contain polyvalent cations only in the fed state or administration of dolutegravir 2 hours before or 6 hours after multivitamins.<sup>1</sup> Prescribing information for the dolutegravir/rilpivirie combination product recommends administration of dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral multivitamins.<sup>3</sup><br><br>The suspected primary mechanism of this interaction is binding of dolutegravir to cations in the gastrointestinal tract to form a poorly-absorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; May 2014.</p>\n<p>2. Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. <i>J Antimicrob Chemother</i>. 2011;66(7):1567-1572. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21493648\">[PubMed 21493648]</a></p>\n<p>3. Juluca (dolutegravir and rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7820":"<p><b>Title</b> Dolutegravir / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer dolutegravir at least 2 hours before or 6 hours after the dose of a multivitamin that contains polyvalent cations (e.g., calcium, iron, magnesium, selenium, zinc). If dolutegravir is administered as part of the dolutegravir/rilpivirine combination product, administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after the multivitamin. Alternatively, dolutegravir and multivitamins can be administered together if taken with food.</p> \n<p><b>Discussion</b> In a clinical study summarized in dolutegravir US prescribing information and subsequently published, simultaneous administration of a magnesium oxide/aluminum oxide containing antacid with dolutegravir (50 mg single dose) decreased the dolutegravir maximum concentration (C<sub>max</sub>), minimum concentration (C<sub>min</sub>), and AUC by 72%, 74%, and 74%, respectively, while administration of the antacid 2 hours after dolutegravir decreased these variables by 18%, 30%, and 26%, respectively.<sup>1,2</sup> Simultaneous coadministration of a high cation containing multivitamin with dolutegravir (50 mg single dose) decreased the dolutegravir Cmax, Cmin, and AUC by 35%, 32%, and 33%, respectively.<sup>1,2</sup> In a pair of clinical studies summarized in dolutegravir US prescribing information, simultaneous administration of ferrous fumarate (324 mg) or calcium carbonate (1,200 mg) with dolutegravir (50 mg single dose) in a fasted state decreased the dolutegravir C<sub>max</sub>, C<sub>min</sub>, and AUC by 47% to 57%, 49% to 56%, and 49% to 54%, respectively. When ferrous fumarate and calcium carbonate were given either 2 hours after dolutegravir or simultaneously with dolutegravir but combined with food, there was no change in dolutegravir C<sub>max</sub>, C<sub>min</sub>, or AUC.<sup>1</sup> <br><br>Thus, the manufacturer recommends co-administration of dolutegravir and multivitamins that contain polyvalent cations only in the fed state or administration of dolutegravir 2 hours before or 6 hours after multivitamins.<sup>1</sup> Prescribing information for the dolutegravir/rilpivirie combination product recommends administration of dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral multivitamins.<sup>3</sup><br><br>The suspected primary mechanism of this interaction is binding of dolutegravir to cations in the gastrointestinal tract to form a poorly-absorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; May 2014.</p>\n<p>2. Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. <i>J Antimicrob Chemother</i>. 2011;66(7):1567-1572. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21493648\">[PubMed 21493648]</a></p>\n<p>3. Juluca (dolutegravir and rilpivirine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7821":"<p><b>Title</b> Dolutegravir / Selenium</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only anticipated with oral administration of selenium.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Selenium may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer dolutegravir at least 2 hours before or 6 hours after oral selenium. If dolutegravir is administered as part of the dolutegravir/rilpivirine combination product, administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral selenium.</p> \n<p><b>Discussion</b> In clinical studies summarized in dolutegravir U.S. prescribing information, simultaneous coadministration of a magnesium oxide/aluminum oxide containing antacid with dolutegravir (50 mg single dose) decreased the dolutegravir maximum concentration (Cmax), minimum concentration (Cmin), and AUC by 72%, 74%, and 74%, respectively, while administration of the antacid 2 hours after dolutegravir decreased these variables by 18%, 30%, and 26%, respectively.<sup>1</sup> Simultaneous coadministration of an unspecified multivitamin with dolutegravir (50 mg single dose) decreased the dolutegravir Cmax, Cmin, and AUC by 35%, 32%, and 33%, respectively.<sup>1</sup> The suspected primary mechanism of these interaction is binding of dolutegravir to cations in gastrointestinal tract to form a poorly-absorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7822":"<p><b>Title</b> Dolutegravir / Zinc Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only anticipated with oral administration of zinc salts.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Zinc Salts may decrease the serum concentration of Dolutegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer dolutegravir at least 2 hours before or 6 hours after oral zinc salts. If dolutegravir is administered as part of the dolutegravir/rilpivirine combination product, administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral zinc salts.</p>\n<div>\n <p><b>Zinc Salts Interacting Members</b> Polaprezinc, Zinc Acetate, Zinc Chloride, Zinc Gluconate, Zinc Sulfate</p>\n</div> \n<p><b>Discussion</b> In clinical studies summarized in dolutegravir U.S. prescribing information, simultaneous coadministration of a magnesium oxide/aluminum oxide containing antacid with dolutegravir (50 mg single dose) decreased the dolutegravir maximum concentration (Cmax), minimum concentration (Cmin), and AUC by 72%, 74%, and 74%, respectively, while administration of the antacid 2 hours after dolutegravir decreased these variables by 18%, 30%, and 26%, respectively.<sup>1</sup> Simultaneous coadministration of an unspecified multivitamin with dolutegravir (50 mg single dose) decreased the dolutegravir Cmax, Cmin, and AUC by 35%, 32%, and 33%, respectively.<sup>1</sup> The suspected primary mechanism of these interaction is binding of dolutegravir to cations in gastrointestinal tract to form a poorly-absorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tivicay (dolutegravir) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7828":"<p><b>Title</b> Repaglinide / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Repaglinide. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible. If these agents are used in combination, monitor for decreased therapeutic effects of repaglinide following rifampin initiation/dose increase, or increased effects following rifampin discontinuation/dose decrease. The timing of doses may substantially affect the magnitude of this interaction; in clinical studies, dosing repaglinide 1 hour after rifampin resulted in the lowest average decrease in repaglinide exposure (compared to 12 h after, 24 h after, or simultaneous dosing).</p> \n<p><b>Discussion</b> In clinical studies of healthy volunteers, the AUC of a single oral dose of repaglinide was reduced in an apparently dose-time-dependent manner by rifampin (600 mg daily in all studies): by 80% when repaglinide (4 mg) was given 24 hours after the last dose of a 7 day rifampin course;<sup>1</sup> by 57% when repaglinide (0.5 mg) was given 12.5 hours after the last dose of a 5 day rifampin course;<sup>2</sup> by 31% when repaglinide (4 mg) was given 1 hour after the last dose of a 7 day rifampin course;<sup>3</sup> and by 48% when repaglinide (4 mg) was given simultaneously with the last dose of a 7 day rifampin course.<sup>1</sup> <br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A and 2C8 mediated repaglinide metabolism. The apparent dependence of the interaction magnitude on dose timing of the drugs may reflect a transient inhibition of active hepatic uptake of repaglinide (e.g., via OATP1B1) by rifampin.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bidstrup TB, Stilling N, Damkier P, et al, “Rifampicin Seems to Act as Both an Inducer and an Inhibitor of the Metabolism of Repaglinide,” <i>Eur J Clin Pharmacol</i>, 2004, 60(2):109-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15034704\">[PubMed 15034704]</a></p>\n<p>2. Niemi M, Backman JT, Neuvonen M, et al, “Rifampin Decreases the Plasma Concentrations and Effects of Repaglinide,” <i>Clin Pharmacol Ther</i>, 2000, 68(5):495-500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11103752\">[PubMed 11103752]</a></p>\n<p>3. Hatorp V, Hansen KT, and Thomsen MS, “Influence of Drugs Interacting With CYP3A4 on the Pharmacokinetics, Pharmacodynamics, and Safety of the Prandial Glucose Regulator Repaglinide,” <i>J Clin Pharmacol</i>, 2003, 43(6):649-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12817528\">[PubMed 12817528]</a></p>\n<p>4. Varma MV, Lin J, Bi YA, et al, “Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin,” <i>Drug Metab Dispos</i>, 2013, 41(5):966-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23393219\">[PubMed 23393219]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7829":"<p><b>Title</b> Perampanel / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Perampanel. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> An increase in the perampanel starting dose to 4 mg/day is recommended when perampanel is used in combination with phenytoin or fosphenytoin. Patients receiving this combination should be followed closely for response, particularly with any changes to phenytoin/fosphenytoin therapy (ie, starting, stopping, dose changes).</p> \n<p><b>Discussion</b> The perampanel AUC was reduced by 43% among patients receiving concurrent phenytoin as compared with patients not receiving enzyme inducing antiepileptic drugs in a population pharmacokinetic analysis based on clinical studies of perampanel.<sup>1</sup> These findings are similar to those from studies of perampanel with oxcarbazepine and carbamazepine where the perampanel AUC was reduced by approximately 50% to 67% by oxcarbazepine and carbamazepine in studies of healthy individuals and in population pharmacokinetic analyses based on data from clinical studies of perampanel.<sup>1</sup> The likely mechanism for this interaction is phenytoin induction of the CYP3A-mediated metabolism of perampanel.<br><br>Based on these findings, the perampanel prescribing information recommends using a higher perampanel starting dose when used together with phenytoin.<sup>1</sup><br><br>Although there was no significant change in phenytoin pharmacokinetics with concurrent perampanel in this population pharmacokinetic analysis,<sup>1</sup> a published case report describes a patient who experienced a greater than 50% reduction in phenytoin concentrations following the initiation of perampanel (2 mg/day for 2 weeks, then increased to 4 mg/day).<sup>2</sup> Following an increase in the phenytoin dose (from 250 mg/day to 350 mg/day) to obtain therapeutic phenytoin concentrations, an increase in the perampanel dose (to 14 mg/day) was followed by another greater than 50% decrease in serum phenytoin concentrations. The mechanism by which perampanel would decrease serum phenytoin concentrations is unclear. Perampanel has been shown to be a weak to moderate inducer of CYP3A4 and possibly of CYP2B6, UGT1A1, and/or UGT1A4;<sup>1</sup> the significance of such effects is not known.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fycompa (perampanel) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; July 2017.</p>\n<p>2. Novy J, Rothuizen LE, Buclin T, et al. Perampanel: a significant liver enzyme inducer in some patients? <i>Eur Neurol</i>. 2014;72(3-4):213-216. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25227593\">[PubMed 25227593]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7830":"<p><b>Title</b> Perampanel / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Perampanel. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> An increase in the perampanel starting dose to 4 mg/day is recommended when perampanel is used in combination with phenytoin or fosphenytoin. Patients receiving this combination should be followed closely for response, particularly with any changes to phenytoin/fosphenytoin therapy (ie, starting, stopping, dose changes).</p> \n<p><b>Discussion</b> The perampanel AUC was reduced by 43% among patients receiving concurrent phenytoin as compared with patients not receiving enzyme-inducing antiepileptic drugs in a population pharmacokinetic analysis based on clinical studies of perampanel.<sup>1</sup> These findings are similar to those from studies of perampanel with oxcarbazepine and carbamazepine where the perampanel AUC was reduced by approximately 50% to 67% by oxcarbazepine and carbamazepine in studies of healthy individuals and in population pharmacokinetic analyses based on data from clinical studies of perampanel.<sup>1</sup> The likely mechanism for this interaction is phenytoin induction of the CYP3A-mediated metabolism of perampanel.<br><br>Based on these findings, the perampanel prescribing information recommends using a higher perampanel starting dose when used together with phenytoin.<sup>1</sup><br><br>Although there was no significant change in phenytoin pharmacokinetics with concurrent perampanel in this population pharmacokinetic analysis,<sup>1</sup> a published case report describes a patient who experienced a greater than 50% reduction in phenytoin concentrations following the initiation of perampanel (2 mg/day for 2 weeks, then increased to 4 mg/day).<sup>2</sup> Following an increase in the phenytoin dose (from 250 mg/day to 350 mg/day) to obtain therapeutic phenytoin concentrations, an increase in the perampanel dose (to 14 mg/day) was followed by another greater than 50% decrease in serum phenytoin concentrations. The mechanism by which perampanel would decrease serum phenytoin concentrations is unclear. Perampanel has been shown to be a weak to moderate inducer of CYP3A4 and possibly of CYP2B6, UGT1A1, and/or UGT1A4;<sup>1</sup> the significance of such effects is not known.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fycompa (perampanel) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; July 2017.</p>\n<p>2. Novy J, Rothuizen LE, Buclin T, et al. Perampanel: a significant liver enzyme inducer in some patients? <i>Eur Neurol</i>. 2014;72(3-4):213-216. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25227593\">[PubMed 25227593]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7831":"<p><b>Title</b> CloZAPine / CYP1A2 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP1A2 Inhibitors (Strong) may increase the serum concentration of CloZAPine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Reduce the dose of clozapine to one-third of the original dose when adding a strong CYP1A2 inhibitor, and monitor patient response closely. Return to the original clozapine dose, as clinically appropriate, when the strong CYP1A2 inhibitor is removed.</p>\n<div>\n <p><b>CYP1A2 Inhibitors (Strong) Interacting Members</b> FluvoxaMINE</p>\n</div> \n<p><b>Discussion</b> Clozapine serum concentrations were an average of 1.4- to 2.6-fold higher with concurrent administration of the strong CYP1A2 inhibitor fluvoxamine, with increases in clozapine serum concentrations (or dose-normalized concentrations) of at least 5-fold in individual subjects/patients, in several studies of this combination.<sup>1,2,3,4,5</sup> Many published case reports similarly describe increased clozapine concentrations and/or effects when combined with fluvoxamine.<sup>6,7,8,9,10,11,12,13</sup><br><br>Additionally, published case reports describe patients who experienced increased clozapine concentrations attributed at least partially to the strong CYP1A2 inhibitor ciprofloxacin.<sup>14,15,16,17,18</sup> According to these reports, clozapine serum concentrations have increased by as much as 2-fold or more in the presence of ciprofloxacin; however, many reports do not provide information on the clozapine concentration before initiation of ciprofloxacin, and factors such as smoking, caffeine consumption, and/or compliance are often inadequately addressed.<br><br>In contrast to these reports of a substantial interaction, a randomized study in seven subjects with schizophrenia but without infection reported only moderate elevation (average 29% increase) of clozapine concentrations with concurrent ciprofloxacin (using a relatively lower dose of 250 mg twice/day).<sup>19</sup> Similarly, a published case report describes no increase in clozapine concentrations despite treatment with ciprofloxacin, suggesting instead that the underlying infection was the potential cause of elevated clozapine concentrations.<sup>20</sup><br><br>Other reports describe fewer clozapine adverse effects with concurrent fluvoxamine (an effect attributed to lower norclozapine concentrations but maintained/elevated parent clozapine concentrations), and use of fluvoxamine as a means of treating clozapine resistance, particularly in patients with genetic variations in CYP1A2 associated with accelerated clozapine metabolism and reduced clozapine concentrations.<sup>21,22,23,24,25</sup><br><br>Based on these data supporting the existence of a significant interaction between clozapine and strong CYP1A2 inhibitors, the clozapine prescribing information recommends reducing the dose of clozapine to one-third of the original dose when adding a strong inhibitor (with a recommended return to the original clozapine dose when the strong inhibitor is removed).<sup>26</sup><br><br>The likely mechanism for this interaction is inhibition of CYP1A2 by fluvoxamine, ciprofloxacin, or other strong CYP1A2 inhibitors, leading to increased clozapine concentrations via reduction of its CYP1A2-mediated metabolism. Clozapine is primarily metabolized by CYP1A2, but enzymes including CYP3A4 and CYP2D6 also appear to participate in clozapine metabolism,<sup>26</sup> perhaps accounting for the relatively moderate changes in clozapine concentrations observed with strong CYP1A2 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wang CY, Zhang ZJ, Li WB, et al. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. <i>J Clin Pharmacol</i>. 2004;44(7):785-792. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15199083\">[PubMed 15199083]</a></p>\n<p>2. Chang WH, Augustin B, Lane HY, et al. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. <i>Psychopharmacology (Berl)</i>. 1999;145(1):91-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10445377\">[PubMed 10445377]</a></p>\n<p>3. Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. <i>J Clin Psychiatry</i>. 2000;61(8):594-599. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10982203\">[PubMed 10982203]</a></p>\n<p>4. Szegedi A, Anghelescu I, Wiesner J, et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. <i>Pharmacopsychiatry</i>. 1999;32(4):148-153. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10505485\">[PubMed 10505485]</a></p>\n<p>5. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. <i>Ther Drug Monit</i>. 1994;16(4):368-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7974626\">[PubMed 7974626]</a></p>\n<p>6. Heeringa M, Beurskens R, Schouten W, Verduijn MM. Elevated plasma levels of clozapine after concomitant use of fluvoxamine. <i>Pharm World Sci</i>. 1999;21(5):243-244. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10550852\">[PubMed 10550852]</a></p>\n<p>7. Kuo FJ, Lane HY, Chang WH. Extrapyramidal symptoms after addition of fluvoxamine to clozapine. <i>J Clin Psychopharmacol</i>. 1998;18(6):483-484. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9864083\">[PubMed 9864083]</a></p>\n<p>8. Armstrong SC, Stephans JR. Blood clozapine levels elevated by fluvoxamine: potential for side effects and lower clozapine dosage. <i>J Clin Psychiatry</i>. 1997;58(11):499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9413421\">[PubMed 9413421]</a></p>\n<p>9. Markowitz JS, Gill HS, Lavia M, Brewerton TD, DeVane CL. Fluvoxamine-clozapine dose-dependent interaction. <i>Can J Psychiatry</i>. 1996;41(10):670-671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8978949\">[PubMed 8978949]</a></p>\n<p>10. Dequardo JR, Roberts M. Elevated clozapine levels after fluvoxamine initiation. <i>Am J Psychiatry</i>. 1996;153(6):840-841. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8633707\">[PubMed 8633707]</a></p>\n<p>11. Koponen HJ, Leinonen E, Lepola U. Fluvoxamine increases the clozapine serum levels significantly. <i>Eur Neuropsychopharmacol</i>. 1996;6(1):69-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8866941\">[PubMed 8866941]</a></p>\n<p>12. Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H. Elevated levels of clozapine in serum after addition of fluvoxamine. <i>J Clin Psychopharmacol</i>. 1994;14(4):279-281. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7962687\">[PubMed 7962687]</a></p>\n<p>13. Gahr M, Rehbaum K, Connemann BJ. Clozapine-associated development of second-onset obsessive compulsive symptoms in schizophrenia: impact of clozapine serum levels and fluvoxamine add-on. <i>Pharmacopsychiatry</i>. 2014;47(3):118-120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24846087\">[PubMed 24846087]</a></p>\n<p>14. Brownlowe K, Sola C. Clozapine toxicity in smoking cessation and with ciprofloxacin. <i>Psychosomatics</i>. 2008;49(2):176. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18354073\">[PubMed 18354073]</a></p>\n<p>15. Sandson NB, Cozza KL, Armstrong SC, Eckermann G, Fischer BA, Phillips B. Clozapine case series. <i>Psychosomatics</i>. 2007;48(2):170-175. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17329613\">[PubMed 17329613]</a></p>\n<p>16. Sambhi RS, Puri R, Jones G. Interaction of clozapine and ciprofloxacin: a case report. <i>Eur J Clin Pharmacol</i>. 2007;63(9):895-896. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17624521\">[PubMed 17624521]</a></p>\n<p>17. Brouwers EE, Sohne M, Kuipers S, et al. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. <i>Clin Drug Investig</i>. 2009;29(1):59-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19067475\">[PubMed 19067475]</a></p>\n<p>18. Markowitz JS, Gill HS, Devane CL, Mintzer JE. Fluoroquinolone inhibition of clozapine metabolism. <i>Am J Psychiatry</i>. 1997;154(6):881. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9167522\">[PubMed 9167522]</a></p>\n<p>19. Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. <i>Eur J Clin Pharmacol</i>. 2000;56(8):585-589. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11151749\">[PubMed 11151749]</a></p>\n<p>20. Espnes KA, Heimdal KO, Spigset O. A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. <i>Ther Drug Monit</i>. 2012;34(5):489-492. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22929408\">[PubMed 22929408]</a></p>\n<p>21. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. <i>J Clin Psychiatry</i>. 2004;65(6):766-771. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15291653\">[PubMed 15291653]</a></p>\n<p>22. Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmacher T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. <i>Psychopharmacology (Berl)</i>. 2000;149(2):163-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10805611\">[PubMed 10805611]</a></p>\n<p>23. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Paplos KG, Roukas DK, Christodoulou GN. Case studies of adjunctive agents in clozapine-resistant schizophrenic patients. <i>Clin Neuropharmacol</i>. 2005;28(1):50-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15711437\">[PubMed 15711437]</a></p>\n<p>24. Eap CB, Bender S, Jaquenoud Sirot E, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. <i>J Clin Psychopharmacol</i>. 2004;24(2):214-219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15206669\">[PubMed 15206669]</a></p>\n<p>25. Ozdemir V, Kalow W, Okey AB, et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C--&gt;A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. <i>J Clin Psychopharmacol</i>. 2001;21(6):603-607. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11763009\">[PubMed 11763009]</a></p>\n<p>26. Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7832":"<p><b>Title</b> PHENobarbital / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may enhance the CNS depressant effect of PHENobarbital. PHENobarbital may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of PHENobarbital. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for unwanted effects of additive CNS depression with the combination of phenobarbital with phenytoin. Plasma concentrations of one or both drugs may also be altered, but effects are variable and the clinical importance of these is unknown.</p> \n<p><b>Discussion</b> Numerous published reports describe reduced serum phenytoin concentrations (or dose-adjusted concentrations) and/or elevated serum phenobarbital concentrations (or dose-adjusted concentrations) in patients receiving the combination of these drugs compared to one of the drugs alone.<sup>1,2,3,4,5,6,7,8,9</sup> Effects are variable, and some patients in published reports exhibited no pharmacokinetic impact on one or both drugs, or the opposite direction of effect, or an effect that varied over time.<sup>3,4,5,10,11</sup> The average pharmacokinetic impact of coadministration of these drugs in two large studies of therapeutic drug monitoring databases were a 10% lower dose-adjusted phenytoin concentration and a 23% greater dose-adjusted phenobarbital concentration.<sup>6,7</sup><br><br>The mechanisms of these interactions are unknown and have not been investigated. Phenobarbital induction of phenytoin metabolism and phenytoin inhibition of phenobarbital metabolism have been speculated in a number of reports to be contributory. Whatever the mechanism, there is a notable absence of data describing the impact of coadministration of these drugs on free/bioactive drug concentrations, and also a notable absence of reports describing clinically significant effects (e.g., toxicity or apparent therapeutic failure), despite extensive clinical experience with this combination. Therefore, there does not presently appear to be sufficient evidence to support a general recommendation for pre-emptive dose adjustment of either drug, or even enhanced monitoring of drug concentrations, when these drugs are used in combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Morselli PL, Rizzo M, and Garattini S, “Interaction Between Phenobarbital and Diphenylhydantoin in Animals and in Epileptic Patients,” <i>Ann NY Acad Sci</i>, 1971, 179:88. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5285399\">[PubMed 5285399]</a></p>\n<p>2. Cucinell SA, Conney AH, Sansur M, et al, “Drug Interactions in Man. I. Lowering Effect of Phenobarbital on Plasma Levels of Bishydroxycoumarin (Dicumarol) and Diphenylhydantoin (Dilantin),” <i>Clin Pharmacol Ther</i>, 1965, 6:420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14314964\">[PubMed 14314964]</a></p>\n<p>3. Buchanan RA, Heffelfinger JC, and Weiss CF, “The Effect of Phenobarbital on Diphenylhydantoin Metabolism in Children,” <i>Pediatrics</i>, 1969, 43:114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5764058\">[PubMed 5764058]</a></p>\n<p>4. Kutt H, Haynes J, Verebely K, et al, “The Effect of Phenobarbital on Plasma Diphenylhydantoin Level and Metabolism in Man and Rat Liver Microsomes,” <i>Neurology</i>, 1969, 19:611. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5814306\">[PubMed 5814306]</a></p>\n<p>5. Garrettson LK and Dayton PG, “Disappearance of Phenobarbital and Diphenylhydantoin From Serum of Children,” <i>Clin Pharmacol Ther</i>, 1970, 11:674. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5455632\">[PubMed 5455632]</a></p>\n<p>6. Fukuoka N, Uno J, Tsukamoto T, et al, “Dose Adjustment of Phenytoin for Comedication in Japanese Patients With Epilepsy,” <i>Ther Drug Monit</i>, 2009, 31(1):57-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19077928\">[PubMed 19077928]</a></p>\n<p>7. Fukuoka N, Tsukamoto T, Uno J, et al, “Influence of Coadministered Antiepileptic Drugs on Serum Phenobarbital Concentrations in Epileptic Patients: Quantitative Analysis Based on a Suitable Transforming Factor,” <i>Biol Pharm Bull</i>, 2004, 27(12):2000-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15577220\">[PubMed 15577220]</a></p>\n<p>8. Nishihara K, Kohda Y, Saitoh Y, et al, “Interaction Between Plasma Phenytoin and Phenobarbital Concentrations in Epileptic Patients,” <i>Folia Psychiatr Neurol Jpn</i>, 1979, 33(3):315-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=520946\">[PubMed 520946]</a></p>\n<p>9. Windorfer A Jr and Sauer W, “Drug Interactions During Anticonvulsant Therapy in Childhood: Diphenylhydantoin, Primidone, Phenobarbitone, Clonazepam, Nitrazepam, Carbamazepin and Dipropylacetate,” <i>Neuropadiatrie</i>, 1977, 8(1):29-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=321985\">[PubMed 321985]</a></p>\n<p>10. Browne TR, Szabo GK, Evans J, et al, “Phenobarbital Does Not Alter Phenytoin Steady-State Serum Concentration or Pharmacokinetics,” <i>Neurology</i>, 1988, 38:639-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3352926\">[PubMed 3352926]</a></p>\n<p>11. Encinas MP, Santos Buelga D, Alonso Gonzalez AC, et al, “Influence of Length of Treatment on the Interaction Between Phenobarbital and Phenytoin,” <i>J Clin Pharm Ther</i>, 1992, 17(1):49-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1548312\">[PubMed 1548312]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7833":"<p><b>Title</b> PHENobarbital / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may enhance the CNS depressant effect of PHENobarbital. Fosphenytoin may increase the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for unwanted effects of additive CNS depression with the combination of phenobarbital with phenytoin. Plasma concentrations of one or both drugs may also be altered, but effects are variable and the clinical importance of these is unknown.</p> \n<p><b>Discussion</b> Numerous published reports describe reduced serum phenytoin concentrations (or dose-adjusted concentrations) and/or elevated serum phenobarbital concentrations (or dose-adjusted concentrations) in patients receiving the combination of these drugs compared to one of the drugs alone.<sup>1,2,3,4,5,6,7,8,9</sup> Effects are variable, and some patients in published reports exhibited no pharmacokinetic impact on one or both drugs, or the opposite direction of effect, or an effect that varied over time.<sup>3,4,5,10,11</sup> The average pharmacokinetic impact of coadministration of these drugs in two large studies of therapeutic drug monitoring databases were a 10% lower dose-adjusted phenytoin concentration and a 23% greater dose-adjusted phenobarbital concentration.<sup>6,7</sup><br><br>The mechanisms of these interactions are unknown and have not been investigated. Phenobarbital induction of phenytoin metabolism and phenytoin inhibition of phenobarbital metabolism have been speculated in a number of reports to be contributory. Whatever the mechanism, there is a notable absence of data describing the impact of coadministration of these drugs on free/bioactive drug concentrations, and also a notable absence of reports describing clinically significant effects (e.g., toxicity or apparent therapeutic failure), despite extensive clinical experience with this combination. Therefore, there does not presently appear to be sufficient evidence to support a general recommendation for pre-emptive dose adjustment of either drug, or even enhanced monitoring of drug concentrations, when these drugs are used in combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Morselli PL, Rizzo M, and Garattini S, “Interaction Between Phenobarbital and Diphenylhydantoin in Animals and in Epileptic Patients,” <i>Ann NY Acad Sci</i>, 1971, 179:88. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5285399\">[PubMed 5285399]</a></p>\n<p>2. Cucinell SA, Conney AH, Sansur M, et al, “Drug Interactions in Man. I. Lowering Effect of Phenobarbital on Plasma Levels of Bishydroxycoumarin (Dicumarol) and Diphenylhydantoin (Dilantin),” <i>Clin Pharmacol Ther</i>, 1965, 6:420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14314964\">[PubMed 14314964]</a></p>\n<p>3. Buchanan RA, Heffelfinger JC, and Weiss CF, “The Effect of Phenobarbital on Diphenylhydantoin Metabolism in Children,” <i>Pediatrics</i>, 1969, 43:114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5764058\">[PubMed 5764058]</a></p>\n<p>4. Kutt H, Haynes J, Verebely K, et al, “The Effect of Phenobarbital on Plasma Diphenylhydantoin Level and Metabolism in Man and Rat Liver Microsomes,” <i>Neurology</i>, 1969, 19:611. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5814306\">[PubMed 5814306]</a></p>\n<p>5. Garrettson LK and Dayton PG, “Disappearance of Phenobarbital and Diphenylhydantoin From Serum of Children,” <i>Clin Pharmacol Ther</i>, 1970, 11:674. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5455632\">[PubMed 5455632]</a></p>\n<p>6. Fukuoka N, Uno J, Tsukamoto T, et al, “Dose Adjustment of Phenytoin for Comedication in Japanese Patients With Epilepsy,” <i>Ther Drug Monit</i>, 2009, 31(1):57-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19077928\">[PubMed 19077928]</a></p>\n<p>7. Fukuoka N, Tsukamoto T, Uno J, et al, “Influence of Coadministered Antiepileptic Drugs on Serum Phenobarbital Concentrations in Epileptic Patients: Quantitative Analysis Based on a Suitable Transforming Factor,” <i>Biol Pharm Bull</i>, 2004, 27(12):2000-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15577220\">[PubMed 15577220]</a></p>\n<p>8. Nishihara K, Kohda Y, Saitoh Y, et al, “Interaction Between Plasma Phenytoin and Phenobarbital Concentrations in Epileptic Patients,” <i>Folia Psychiatr Neurol Jpn</i>, 1979, 33(3):315-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=520946\">[PubMed 520946]</a></p>\n<p>9. Windorfer A Jr and Sauer W, “Drug Interactions During Anticonvulsant Therapy in Childhood: Diphenylhydantoin, Primidone, Phenobarbitone, Clonazepam, Nitrazepam, Carbamazepin and Dipropylacetate,” <i>Neuropadiatrie</i>, 1977, 8(1):29-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=321985\">[PubMed 321985]</a></p>\n<p>10. Browne TR, Szabo GK, Evans J, et al, “Phenobarbital Does Not Alter Phenytoin Steady-State Serum Concentration or Pharmacokinetics,” <i>Neurology</i>, 1988, 38:639-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3352926\">[PubMed 3352926]</a></p>\n<p>11. Encinas MP, Santos Buelga D, Alonso Gonzalez AC, et al, “Influence of Length of Treatment on the Interaction Between Phenobarbital and Phenytoin,” <i>J Clin Pharm Ther</i>, 1992, 17(1):49-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1548312\">[PubMed 1548312]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7834":"<p><b>Title</b> Phenytoin / Omeprazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Omeprazole. Omeprazole may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for diminished therapeutic effects of omeprazole as well as for increased serum phenytoin concentrations (the latter particularly with daily omeprazole doses of 40 mg or greater) whenever these agents are used in combination. Lower omeprazole doses (ie, 20 mg/day) and other proton pump inhibitors (eg, lansoprazole, rabeprazole, pantoprazole) may be less likely to elevate phenytoin serum concentrations.</p> \n<p><b>Discussion</b> The clearance of phenytoin (250 mg IV single dose) was decreased by 15% in 8 healthy volunteers when administered following a 1-week course of omeprazole (40 mg/day).<sup>1</sup> Similarly, the AUC of phenytoin (300 mg oral single dose) was increased 24% in 10 healthy volunteers when administered following a 9-day course of omeprazole (40 mg/day).<sup>2</sup> In contrast, serum phenytoin concentrations (“steady state”) did not change significantly in any of 8 patients following 3 weeks of concomitant therapy with omeprazole at a dose of 20 mg/day,<sup>3</sup> nor were phenytoin pharmacokinetics altered following 4 days of omeprazole 40 mg/day in a study of 18 healthy volunteers.<sup>4</sup><br><br>The suspected primary mechanism leading to the above effects is omeprazole inhibition of CYP2C19-mediated phenytoin metabolism. In addition to this effect, phenytoin induction of omeprazole metabolism (via CYP2C19 and/or CYP3A4) could theoretically significantly reduce omeprazole exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. <i>Gastroenterology</i>. 1985;89(6):1235-1241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3932118\">[PubMed 3932118]</a></p>\n<p>2. Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. <i>Br J Clin Pharmacol</i>. 1987;24(4):543-545. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3689634\">[PubMed 3689634]</a></p>\n<p>3. Andersson T, Lagerstrom PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. <i>Ther Drug Monit</i>. 1990;12(4):329-333. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2396305\">[PubMed 2396305]</a></p>\n<p>4. Bachmann KA, Sullivan TJ, Jauregui L, Reese JH, Miller K, Levine L. Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. <i>Br J Clin Pharmacol</i>. 1993;36(4):380-382. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12959321\">[PubMed 12959321]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7835":"<p><b>Title</b> Omeprazole / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Omeprazole may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Omeprazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for diminished therapeutic effects of omeprazole as well as for increased serum phenytoin concentrations (the latter particularly with daily omeprazole doses of 40 mg or greater) whenever these agents are used in combination. Lower omeprazole doses (e.g., 20 mg/day) and other proton pump inhibitors (e.g., lansoprazole, rabeprazole, pantoprazole) may be less likely to elevate phenytoin serum concentrations.</p> \n<p><b>Discussion</b> The clearance of phenytoin (250 mg IV single dose) was decreased by 15% in 8 healthy volunteers when administered following a 1-week course of omeprazole (40 mg/day).<sup>1</sup> Similarly, the AUC of phenytoin (300 mg oral single dose) was increased 24% in 10 healthy volunteers when administered following a 9-day course of omeprazole (40 mg/day).<sup>2</sup> In contrast, serum phenytoin concentrations (“steady state”) did not change significantly in any of 8 patients following 3 weeks of concomitant therapy with omeprazole at a dose of 20 mg/day,<sup>3</sup> nor were serum phenytoin concentrations altered in several clinical studies using other proton pump inhibitors (lansoprazole, pantoprazole, rabeprazole).<sup>4,5,6</sup><br><br>The suspected primary mechanism leading to the above effects is omeprazole inhibition of CYP2C19 mediated phenytoin metabolism. In addition to this effect, phenytoin induction of omeprazole metabolism (primarily via CYP2C19, but also possibly via other pathways including CYP3A4) could theoretically significantly reduce omeprazole exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gugler R and Jensen JC, “Omeprazole Inhibits Oxidative Drug Metabolism,” <i>Gastroenterology</i>, 1985, 89(6):1235-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3932118\">[PubMed 3932118]</a></p>\n<p>2. Prichard PJ, Walt RP, Kitchingman GK, et al, “Oral Phenytoin Pharmacokinetics During Omeprazole Therapy,” <i>Br J Clin Pharmacol</i>, 1987, 24(4):543-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3689634\">[PubMed 3689634]</a></p>\n<p>3. Andersson T, Lagerstrom PO, and Unge P, “A Study of the Interaction Between Omeprazole and Phenytoin in Epileptic Patients,” <i>Ther Drug Monit</i>, 1990, 12(4):329-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2396305\">[PubMed 2396305]</a></p>\n<p>4. Karol MD, Locke CS, and Cavanaugh JH, “Lack of a Pharmacokinetic Interaction Between Lansoprazole and Intravenously Administered Phenytoin,” <i>J Clin Pharmacol</i>, 1999, 39(12):1283-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10586395\">[PubMed 10586395]</a></p>\n<p>5. Humphries TJ, Nardi, RV, Lazar JD, et al, “Drug-drug Interaction Evaluation of Rabeprazole Sodium: A Clean/Expected Slate?,” <i>Gut</i>, 1996, 39(Suppl 3):A47. [abstract]</p>\n<p>6. Middle MV, Muller FO, Schall R, et al, “No Influence of Pantoprazole on the Pharmacokinetics of Phenytoin,” <i>Int J Clin Pharmacol Ther</i>, 1996, 34(Supp 1):S72-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8793606\">[PubMed 8793606]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7836":"<p><b>Title</b> Fosphenytoin / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> When possible, seek alternatives to this combination. If these agents are used together, monitor closely for decreased concentrations/therapeutic effects of phenytoin if rifampin is initiated/dose increased, or increased concentrations/effects if rifampin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The clearance of phenytoin (100 mg single intravenous dose) more than doubled in 6 patients when administered following a 2-week course of rifampin (450 mg/day).<sup>1</sup> Case reports describe both phenytoin toxicity<sup>2</sup> and reduced efficacy<sup>3</sup> in patients following the withdrawal and initiation, respectively, of rifampin therapy. <br><br>The likely primary mechanism of this interaction is rifampin induction of CYP2C9 and 2C19 mediated phenytoin metabolism. Addition of isoniazid, a strong CYP2C19 inhibitor, did not reverse rifampin's effects on phenytoin metabolism.<sup>1</sup> Rifabutin and rifapentine, generally weaker CYP inducers than rifampin, would likely have a lesser effect on phenytoin concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kay L, Kampmann JP, Svendsen TL, et al, “Influence of Rifampicin and Isoniazid on the Kinetics of Phenytoin,”<i>Br J Clin Pharmacol</i>, 1985, 20:323-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4074601\">[PubMed 4074601]</a></p>\n<p>2. Abajo FJ, “Phenytoin Interaction With Rifampicin,” <i>Br Med J</i>, 1988, 297:1048. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3142625\">[PubMed 3142625]</a></p>\n<p>3. Wagner JC, “Rifampicin-Phenytoin Drug Interaction,” <i>Drug Intell Clin Pharm</i>, 1984, 18:497.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7837":"<p><b>Title</b> Phenytoin / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Phenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> When possible, seek alternatives to this combination. If these agents are used together, monitor closely for decreased concentrations/therapeutic effects of phenytoin if rifampin is initiated/dose increased, or increased concentrations/effects if rifampin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The clearance of phenytoin (100 mg single intravenous dose) more than doubled in 6 patients when administered following a 2-week course of rifampin (450 mg/day).<sup>1</sup> Case reports describe both phenytoin toxicity<sup>2</sup> and reduced efficacy<sup>3</sup> in patients following the withdrawal and initiation, respectively, of rifampin therapy. <br><br>The likely primary mechanism of this interaction is rifampin induction of CYP2C9 and 2C19 mediated phenytoin metabolism. Addition of isoniazid, a strong CYP2C19 inhibitor, did not reverse rifampin's effects on phenytoin metabolism.<sup>1</sup> Rifabutin and rifapentine, generally weaker CYP inducers than rifampin, would likely have a lesser effect on phenytoin concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kay L, Kampmann JP, Svendsen TL, et al, “Influence of Rifampicin and Isoniazid on the Kinetics of Phenytoin,”<i>Br J Clin Pharmacol</i>, 1985, 20:323-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4074601\">[PubMed 4074601]</a></p>\n<p>2. Abajo FJ, “Phenytoin Interaction With Rifampicin,” <i>Br Med J</i>, 1988, 297:1048. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3142625\">[PubMed 3142625]</a></p>\n<p>3. Wagner JC, “Rifampicin-Phenytoin Drug Interaction,” <i>Drug Intell Clin Pharm</i>, 1984, 18:497.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7838":"<p><b>Title</b> CloZAPine / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of CloZAPine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Clozapine prescribing information cautions that concurrent use with a strong CYP3A4 inducer is not recommended but that if such a combination is necessary, increased clozapine doses may be required. Any patient required to use such a combination should have their response to clozapine monitored closely. Clozapine dose reduction and further monitoring may be required upon discontinuation of a CYP3A4 inducer in patients who had been maintained on the combination.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Clozapine prescribing information cautions that concurrent use with a strong CYP3A4 inducer is not recommended but that if such a combination is necessary, increased clozapine doses may be required.<sup>1</sup> Clozapine is metabolized by CYP1A2 (primarily), CYP2D6, and CYP3A4, and it is expected that concurrent use with strong enzyme inducers would lead to reduced clozapine concentrations due to enhanced elimination.<br><br>Case reports with the strong inducer carbamazepine and with St Johns Wort describe reduced clozapine concentrations (47-50% reductions in concentration or concentration/dose ratio) and worsening of psychiatric symptoms.<sup>2,3,4</sup> Another report describes a significant increase in clozapine concentrations and adverse effects following a change from carbamazepine to oxcarbazepine, an antiepileptic associated with less CYP3A4 induction.<sup>5</sup><br><br>Similarly, reports with the inducers phenytoin and rifampin describe reduced clozapine concentrations and effectiveness with concurrent therapy.<sup>6,7,8</sup><br><br>Of note, some reports have suggested that concurrent use of clozapine with enzyme inducers such as carbamazepine may also be associated with a greater risk for clozapine adverse effects,<sup>9,10</sup> an effect that may be related to the relatively greater concentration of metabolites such as norclozapine.<sup>11</sup> The true clinical significance of any such shift in metabolite concentrations is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Clozaril</i> (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2014.</p>\n<p>2. Van Strater AC, Bogers JP. Interaction of St Johns wort (hypericum perforatum) with clozapine. <i>Int Clin Psychopharmacol</i>. 2012;27(2):121-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22113252\">[PubMed 22113252]</a></p>\n<p>3. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. <i>Pharmacopsychiatry</i>. 1995;28(1):26-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7746842\">[PubMed 7746842]</a></p>\n<p>4. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. <i>Ther Drug Monit</i>. 1994;16(4):368-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7974626\">[PubMed 7974626]</a></p>\n<p>5. Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report. <i>Psychopharmacology (Berl)</i>. 1994;116(1):115-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7862923\">[PubMed 7862923]</a></p>\n<p>6. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. <i>J Clin Psychiatry</i>. 1991;52(1):23-25. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1988414\">[PubMed 1988414]</a></p>\n<p>7. Peritogiannis V, Pappas D, Antoniou K, Hyphantis T, Mavreas V. Clozapine-rifampicin interaction in a patient with pulmonary tuberculosis. <i>Gen Hosp Psychiatry</i>. 2007;29(3):281-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17484952\">[PubMed 17484952]</a></p>\n<p>8. Joos AA, Frank UG, Kaschka WP. Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection. <i>J Clin Psychopharmacol</i>. 1998;18(1):83-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9472849\">[PubMed 9472849]</a></p>\n<p>9. Muller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. <i>Lancet</i>. 1988;2(8626-8627):1500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2904624\">[PubMed 2904624]</a></p>\n<p>10. Junghan U, Albers M, Woggon B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? <i>Pharmacopsychiatry</i>. 1993;26(6):262. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8127933\">[PubMed 8127933]</a></p>\n<p>11. Langbehn DR, Alexander B. Increased risk of side-effects in psychiatric patients treated with clozapine and carbamazepine: a reanalysis. <i>Pharmacopsychiatry</i>. 2000;33(5):196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11071023\">[PubMed 11071023]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7839":"<p><b>Title</b> MetFORMIN / Topiramate</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Laboratory/Diagnostic Result</b>: Acidosis, which is frequently associated with topiramate therapy, is a contraindication for metformin. Patients without acidosis may receive the combination but should be monitored for development of acidosis.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Topiramate may enhance the adverse/toxic effect of MetFORMIN. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of acidosis. Metformin is contraindicated in patients with metabolic acidosis, a condition that is not infrequently associated with topiramate therapy.</p> \n<p><b>Discussion</b> Metformin is contraindicated in patients with chronic or acute acidosis,<sup>1</sup> and given the potential for topiramate to cause metabolic acidosis, the topiramate prescribing information notes that concurrent use with metformin is contraindicated in patients with metabolic acidosis.<sup>2,3</sup><br><br>The primary concern with this combination is the potential for metformin to cause lactic acidosis, a condition estimated to have a frequency of 3 cases per 100,000 patient-years of metformin treatment.<sup>1</sup> Preexisting acidosis due to other conditions, such as topiramate therapy, may increase the risk for metformin-associated lactic acidosis. According to a review on the subject, topiramate causes decreased bicarbonate concentrations in approximately 32-48% of patients (at 400 mg/day), with a more severe decrease in approximately 7% of patients.<sup>4</sup><br><br>Of note, there has been interest in using metformin and topiramate together to treat obesity. Though the studies on the subject are relatively small in size (for detection of relatively rare toxicities), these studies have not described lactic acidosis with the combination.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Glucophage XR (metformin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; August 2008.</p>\n<p>2. Trokendi XR (topiramate) [prescribing information]. Rockville, MD: Supernus Pharmaceuticals, Inc.; August 2013.</p>\n<p>3. Topamax (topiramate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; October 2012.</p>\n<p>4. Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: extent, mechanism and effects. <i>Br J Clin Pharmacol</i>. 2009;68(5):655-661. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19916989\">[PubMed 19916989]</a></p>\n<p>5. Rosenstock J, Hollander P, Gadde KM, et al. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. <i>Diabetes Care</i>. 2007;30(6):1480-1486. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17363756\">[PubMed 17363756]</a></p>\n<p>6. Toplak H, Hamann A, Moore R, et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. <i>Int J Obes (Lond)</i>. 2007;31(1):138-146. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16703004\">[PubMed 16703004]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7840":"<p><b>Title</b> Topiramate / Alcohol (Ethyl)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: There are additional significant interaction concerns that are specific to the use of extended-release topiramate capsules (Trokendi XR brand).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Topiramate. Alcohol (Ethyl) may increase the serum concentration of Topiramate. This applies specifically to use with the extended-release topiramate capsules (Trokendi XR). Also, topiramate concentrations may be subtherapeutic in the later portion of the dosage interval. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of alcohol within 6 hours of ingestion of extended-release topiramate (Trokendi XR) (i.e., from 6 hours prior to ingestion through 6 hours after ingestion) is contraindicated. Any use of alcohol with topiramate should be avoided when possible and should only be undertaken with extreme caution.</p> \n<p><b>Discussion</b> Due to evidence that alcohol can alter the release characteristics of extended-release topiramate capsules (Trokendi XR brand), use of alcohol within 6 hours of ingestion of extended-release topiramate (Trokendi XR) (i.e., from 6 hours prior to ingestion through 6 hours after ingestion) is contraindicated.<sup>1</sup> According to the prescribing information, alcohol may cause an excessive release of topiramate from the capsules, resulting in increased topiramate concentrations and possible toxicity soon after ingestion. In addition, due to the early release of the dose, topiramate concentrations may be subtherapeutic during the later part of the dosing interval, leading to a risk of inadequate anti-seizure activity.<br><br>Because of the potential for topiramate to cause CNS depression and/or other neuropsychiatric or cognitive adverse effects, use of alcohol even with immediate-release topiramate dosage forms should only be undertaken with extreme caution.<sup>2</sup> Whenever possible, avoidance of this combination seems advisable.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Trokendi XR (topiramate). Rockville, MD: Supernus Pharmaceuticals, Inc., August 2013.</p>\n<p>2. Prescribing information. Topamax (topiramate). Titusville, NJ: Janssen Pharmaceuticals, Inc., October 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7841":"<p><b>Title</b> CNS Depressants / Tapentadol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tapentadol may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug to the minimum possible while achieving the desired clinical effect. Start tapentadol at a dose of one-third to one-half of the normal dose if being initiated in a patient who is taking another drug with CNS depressant effects. Consider reducing the dose of the other CNS depressant when possible. Warn patients and caregivers about the risk of slowed or difficult breathing and/or sedation and monitor patients closely for evidence of excessive CNS depression (eg, respiratory depression, hypotension, and excessive sedation).</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The US Food and Drug Administration (FDA) issued a drug safety communication stating that the combined use of opioid medicines with benzodiazepines or other drugs that<br>depress the CNS has resulted in serious side effects, including slowed or difficult breathing and deaths.<sup>1</sup> The labels of all opioid medications and benzodiazepines will be updated to include a boxed warning describing this alert.<sup>1</sup><br><br>A cohort study conducted in North Carolina found that the risk of opioid-related overdose death was 10-fold higher in patients who also received benzodiazepines (7.0 per 10,000 person-years; 95% CI 6.3 to 7.8) compared with patients who received opioids alone (0.7 per 10,000 person years; 95% CI 0.6 to 0.9).<sup>2</sup> In another analysis of patients receiving opioids in the Veterans Health Administration database, the risk of death from drug overdose was significantly higher among patients prescribed concomitant benzodiazepines compared with those receiving opioids alone (hazard ratio 3.86; 95% CI 3.49 to 4.26).<sup>3</sup> Additional analyses have concluded that other CNS depressants (eg, antipsychotics, antidepressants, antiepileptics) and alcohol are often implicated in opioid-related overdose and death.<sup>4,5</sup><br><br>Tapentadol prescribing information recommends starting tapentadol at a dose of one-third to one-half of the normal dose if being initiated in a patient who is taking another drug with CNS depressant effects.<sup>6</sup> The recommendation further suggests consideration of a reduction in the dose of the other CNS depressant. This warning is due to the potential for additive or synergistic CNS depression, leading to an increased risk of adverse effects such as respiratory depression, hypotension, excessive sedation, and coma.</p> \n<p><b>Footnotes</b> </p>\n<p>1. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. http://www.fda.gov/Drugs/DrugSafety/ucm518473.htm. Published August 31, 2016. Accessed September 8, 2016.</p>\n<p>2. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. <i>Pain Med</i>. 2016;17(1):85-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26333030\">[PubMed 26333030]</a></p>\n<p>3. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study [published online June 10, 2015]. <i>BMJ</i>. doi: 10.1136/bmj.h2698. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26063215\">[PubMed 26063215]</a></p>\n<p>4. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. <i>JAMA</i>. 2013;309(7):657-659. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23423407\">[PubMed 23423407]</a></p>\n<p>5. Jones CM, Paulozzi LJ, Mack KA; Centers for Disease Control and Prevention (CDC). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths-United States, 2010. <i>MMWR Morb Mortal Wkly Rep</i>. 2014;63(40):881-885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25299603\">[PubMed 25299603]</a></p>\n<p>6. Nucynta (tapentadol) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; July 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7842":"<p><b>Title</b> Ciprofloxacin (Systemic) / OxyCODONE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> OxyCODONE may enhance the adverse/toxic effect of Ciprofloxacin (Systemic). Specifically, the risk of myoclonus may be increased with this combination. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Consider monitoring patients receiving oxycodone and ciprofloxacin in combination for development of myoclonus.</p> \n<p><b>Discussion</b> A single published case report describes an 80 year old woman who developed intermittent myoclonic jerking in both arms following 7 days of concomitant treatment with ciprofloxacin (500 mg orally twice daily) and oxycodone (5 mg orally twice daily for 4 days, then 10 mg twice daily).<sup>1</sup> Ciprofloxacin was discontinued the day myoclonus was first detected, then oxycodone was tapered off 6 days later. Two days after oxycodone discontinuation, myoclonic symptoms resolved.<br><br>The mechanism of this possible interaction is not clear. Both oxycodone and ciprofloxacin have been reported as potential independent causes of twitching, and ciprofloxacin has been reported specifically as a potential cause of myoclonus.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gopinath KG, Hewton C and Shibu PK, “Myoclonus Associated With Concomitant Ciprofloxacin and Oxycodone in an Older Patient,” <i>Br J Clin Pharmacol</i>, 2013 July 23. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23879446\">[PubMed 23879446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7843":"<p><b>Title</b> Telaprevir / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Telaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of strong CYP3A inducers with telaprevir is contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Telaprevir prescribing information lists as contraindicated concurrent therapy with any strong inducers of the CYP3A4 enzyme.<sup>1</sup> Despite this, however, recommendations in some parts of the prescribing information for drugs such as carbamazepine, phenytoin, and phenobarbital, which are generally considered to be potent CYP3A4 inducers,<sup>2,3</sup> call for monitoring of telaprevir response and anti-seizure drug concentrations and response. However, considering the importance of maintaining effective concentrations of telaprevir and the induction potential of these drugs, it seems prudent to avoid such combinations whenever possible.<br><br>The specific mechanism for this predicted interaction is induction of CYP3A, leading to increased telaprevir metabolism and decreased telaprevir serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated, May 2011.</p>\n<p>2. Ohno Y, Hisaka A, Ueno M, et al, “General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information,” <i>Clin Pharmacokinet</i>, 2008, 47(10):669-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18783297\">[PubMed 18783297]</a></p>\n<p>3. Ripp SL, Mills JB, Fahmi OA, et al, “Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 Induction,” <i>Drug Metab Dispos</i>, 2006, 34(10):1742-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16837568\">[PubMed 16837568]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7844":"<p><b>Title</b> Levomilnacipran / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Levomilnacipran. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Do not exceed a maximum adult levomilnacipran dose of 80 mg/day in patients also receiving strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in levomilnacipran U.S. prescribing information, coadministration of ketoconazole increased the levomilnacipran maximum concentration and AUC by 1.25-1.50 and 1.50-1.75 fold, respectively (exact figures not reported).<sup>1</sup> The presumed primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated levomilnacipran metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fetzima (levomilnacipran). St. Louis, MO: Forest Laboratories, Inc., July 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7845":"<p><b>Title</b> Levomilnacipran / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alcohol (Ethyl) may increase the absorption of Levomilnacipran. More specifically, Alcohol (Ethyl) may cause more rapid release of Levomilnacipran from extended-release tablets, which could accelerate absorption early post-dose. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid administering levomilnacipran with alcohol due to possible changes in levomilnacipran release and absorption early post-dose. The use of alcohol in patients receiving levomilnacipran is not otherwise advised against, although it may theoretically modify the central effects of one or both drugs.</p> \n<p><b>Discussion</b> An in vitro study summarized in levomilnacipran U.S. prescribing information indicated a potential for alcohol to accelerate release of levomilnacipran from extended-release tablets.<sup>1</sup> Consequently, taking levomilnacipran with alcohol is specifically advised against.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fetzima (levomilnacipran). St. Louis, MO: Forest Laboratories, Inc., July 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7846":"<p><b>Title</b> Vitamin K Antagonists / Levomilnacipran</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Levomilnacipran may enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor anticoagulant response closely in patients who are also being treated with levomilnacipran, as levomilnacipran may interfere with platelet function leading to a possible increase in the risk for bleeding.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> Based on data suggesting that other serotonin reuptake inhibitors may impair platelet function and/or possibly cause bleeding, levomilnacipran prescribing information cautions that concurrent use with warfarin may be associated with a greater risk for bleeding.<sup>1</sup><br><br>Several case-control studies have reported an association between the combination of SNRIs and NSAIDs and the risk of bleeding, though most have only evaluated the SNRIs in combination with selective serotonin reuptake inhibitors (SSRIs) and/or tricyclic antidepressants (both of which have been independently associated with altered platelet function and increased bleeding risk).<sup>2,3,4,5,6</sup> Of note, the interaction between intermediate serotonin inhibitors (group including the SNRI venlafaxine) and NSAIDs was significant only for non-selective NSAIDs, and not for the COX-2 inhibitors, in one study.<sup>4</sup> In another, there was evidence of a synergistic interaction on bleeding risk for the SSRI-NSAID interaction, but the interaction between non-selective reuptake inhibitors (including venlafaxine) and NSAIDs was simply additive.<sup>5</sup> In contrast, two more recent case-control studies reported that the association between venlafaxine use and GI bleeding was even greater than that reported with the SSRIs.<sup>2,3</sup><br><br>Case reports describe bleeding and impaired platelet function in patients receiving the SNRIs venlafaxine or duloxetine, though none describe bleeding associated with an SNRI-warfarin combination.<sup>7,8,9,10</sup><br><br>The suspected mechanism for much of this reported increase in bleeding risk involves both the reduction of gastroprotective prostaglandins by NSAIDs and the antiplatelet effects of both NSAIDs and drugs inhibiting serotonin reuptake.<sup>11</sup> This dual mechanism is important as it seems that existing tissue damage (e.g., NSAID-related gastric erosions) is critical for the appearance of bleeding associated with this interaction.<sup>12</sup> Such absence of a source of tissue damage has been cited as a reason for such a lower absolute risk of cerebrovascular vs. gastrointestinal bleeding with the combination.<sup>11,12</sup> This point raises certain questions about the degree of risk associated with concurrent use of an SNRI and warfarin (due to lack of NSAID- or aspirin-related tissue damage). Several potential mechanisms for an antiplatelet effect of the serotonin-altering antidepressants have been reported, but the primary suspected mechanism involves depletion of platelet serotonin concentrations.<sup>13</sup> Serotonin enhances platelet aggregation, and since platelets cannot synthesize serotonin; transporter-mediated uptake from blood is required for maintenance of normal intra-platelet serotonin concentrations. Inhibition of this uptake by SNRIs is thought to lead to a gradual depletion of platelet serotonin and, consequently, to impaired platelet aggregation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fetzima (levomilnacipran). St. Louis, MO: Forest Laboratories, Inc., July 2013.</p>\n<p>2. Opatrny L, Delaney JA, Suissa S, “Gastro-Intestinal Haemorrhage Risks of Selective Serotonin Receptor Anatgonist Therapy: A New Look,” <i>Br J Clin Pharmacol</i>, 2008, 66(1):76-81.</p>\n<p>3. de Abajo FJ, Garcia-Rodriguez LA, “Risk of Upper Gastrointestinal Tract Bleeding Associated with Selective Serotonin Reuptake Inhibitors and Venlafaxine Therapy,” <i>Arch Gen Psychiatry</i>, 2008, 65(7):795-803.</p>\n<p>4. Wessinger S, Kaplan M, Choi L, et al, “Increased Use of Selective Serotonin Reuptake Inhibitors in Patients Admitted with Gastrointestinal Haemorrhage: a Multicentre Retrospective Analysis,” <i>Aliment Pharmacol Ther</i>, 2006, 23:937-44.</p>\n<p>5. de Abajo FJ, Rodriguez LAG, Montero D, “Association Between Selective Serotonin Reuptake Inhibitors and Upper Gastrointestinal Bleeding: Population Based Case-Control Study,” <i>BMJ</i>, 1999, 319:1106-9.</p>\n<p>6. van Walraven C, Mamdani MM, Wells PS, et al, “Inhibition of Serotonin Reuptake by Antidepressants and Upper Gastrointestinal Bleeding in Elderly Patients: Retrospective Cohort Study,” <i>BMJ</i>, 2001, 323:655-8.</p>\n<p>7. Yavasoglu I, Kadikoylu G,Bolaman Z, “Gingival Bleeding Due to Venlafaxine,” <i>Ann Pharmacother</i>, 2008, 42:144-5.</p>\n<p>8. Balhara Y, Sagar R,Varghese ST, “Bleeding Gums: Duloxetine May Be the Cause,” <i>J Postgrad Med</i>, 2007, 53:44-5.</p>\n<p>9. Sarma A,Horne MK, 3rd, “Venlafaxine-Induced Ecchymoses and Impaired Platelet Aggregation,” <i>Eur J Haematol</i>, 2006, 77:533-7.</p>\n<p>10. Kohn S,Labbate LA, “Venlafaxine and Ecchymosis,” <i>Can J Psychiatry</i>, 1997, 42:91.</p>\n<p>11. Mort JR, Aparasu RR, Baer RK, “ Interaction Between Selective Serotonin Reuptake Inhibitors and Nonsteroidal Antiinflammatory Drugs: Review of the Literature,” <i>Pharmacotherapy</i>, 2006, 26(9):1307-13.</p>\n<p>12. Weinrieb RM, Auriacombe M, Lynch KG, et al, “Selective Serotonin Re-Uptake Inhibitors and the Risk of Bleeding,” <i>Expert Opin Drug Saf</i>, 2005, 4:337-44.</p>\n<p>13. Turner MS, May DB, Arthur RR, et al, “Clinical Impact of Selective Serotonin Reuptake Inhibitors Therapy with Bleeding Risks,” <i>J Intern Med</i>, 2007, 261:205-13.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7848":"<p><b>Title</b> CNS Depressants / Brimonidine (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Brimonidine (Topical) may enhance the CNS depressant effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients extra closely for evidence of excessive CNS depression (e.g., fatigue, depression, altered mental status, etc.) when topical brimonidine is used together with a CNS depressant medication.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The prescribing information for topical brimonidine cautions that concurrent use with CNS depressants may result in excessive CNS depression.<sup>1</sup><br><br>One published report describes two infants who experienced bradycardia, hypotension, and CNS depression that was attributed to the concurrent use of ophthalmic brimonidine and a beta-blocker.<sup>2</sup> Though not specifically describing an interaction, other case reports describe systemic effects (unresponsiveness, altered mental status, hypotension, bradycardia) attributed to ophthalmic brimonidine when used in pediatric patients.<sup>3,4</sup> An analysis of 30 pediatric patients (mean age = 10.5 years) treated with ophthalmic brimonidine found that 7 patients (23%) experienced systemic effects ranging from fatigue to repeatedly being unarousable following brimonidine administration.<sup>5</sup><br><br>Of note, although use of topical brimonidine does appear to result in some systemic absorption, the prescribing information does not cite any reports of adverse effects consistent with bradycardia, hypotension, or CNS depression.<sup>1</sup><br><br>The likely mechanism for any such interaction is systemic alpha2-agonist actions (including sedation, depression, etc.) of absorbed brimonidine leading to additive or synergistic CNS depressant effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Mirvaso (brimonidine). Fort Worth, TX: Galderma Laboratories, L.P., August 2013.</p>\n<p>2. Mungan NK, Wilson TW, Nischal KK, et al, “Hypotension and Bradycardia in Infants after the Use of Topical Brimonidine and Beta-Blockers,” <i>J AAPOS</i>, 2003, 7(1):69-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12690374\">[PubMed 12690374]</a></p>\n<p>3. Rangan C, Everson G, Cantrell FL, “Central Alpha-2 Adrenergic Eye Drops: Case Series of 3 Pediatric Systemic Poisonings,” <i>Pediatr Emerg Care</i>, 2008, 24(3):167-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18347496\">[PubMed 18347496]</a></p>\n<p>4. Berlin RJ, Lee UT, Samples JR, et al, “Ophthalmic Drops Causing Coma in an Infant,” <i>J Pediatr</i>, 2001, 138(3):441-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11241061\">[PubMed 11241061]</a></p>\n<p>5. Enyedi LB, Freedman SF, “Safety and Efficacy of Brimonidine in Children with Glaucoma,” <i>J AAPOS</i>, 2001, 5(5):281-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11641636\">[PubMed 11641636]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7849":"<p><b>Title</b> Brimonidine (Topical) / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Brimonidine (Topical). Monoamine Oxidase Inhibitors may increase the serum concentration of Brimonidine (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients extra closely for evidence of excessive cardiovascular and/or CNS depressant effects (e.g., fatigue, depression, altered mental status, etc.) when topical brimonidine is used together with a monoamine oxidase inhibitor (MAOI).</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The prescribing information for topical brimonidine cautions that concurrent use with monoamine oxidase inhibitors (MAOIs) may result in excessive systemic brimonidine effects such as hypotension, bradycardia, and/or CNS depression.<sup>1</sup><br><br>A study evaluating the cardiovascular effects of ophthalmic brimonidine, compared to ophthalmic timolol (0.5%) and betaxolol (0.25%) found that brimonidine reduced systolic blood pressure by 5.2 to 7.3 mmHg more than timolol or betaxolol (n=24 healthy volunteers).<sup>2</sup><br><br>One published report describes two infants who experienced bradycardia, hypotension, and CNS depression that was attributed to the concurrent use of ophthalmic brimonidine and a beta-blocker.<sup>3</sup> Though not specifically describing an interaction, post-marketing reports and other published case reports describe systemic effects (unresponsiveness, altered mental status, hypotension, bradycardia) attributed to ophthalmic brimonidine when used in pediatric patients.<sup>4,5,6</sup> An analysis of 30 pediatric patients (mean age = 10.5 years) treated with ophthalmic brimonidine found that 7 patients (23%) experienced systemic effects ranging from fatigue to repeatedly being unarousable following brimonidine administration.<sup>7</sup><br><br>Of note, although use of topical brimonidine does appear to result in some systemic absorption, the prescribing information does not cite any reports of adverse effects consistent with bradycardia, hypotension, or CNS depression.<sup>1</sup><br><br>It is suspected that MAOIs, which can independently cause significant cardiac and CNS effects and may alter the metabolism of alpha2-agonists such as brimonidine, can increase the risks for and severity of such effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Mirvaso (brimonidine). Fort Worth, TX: Galderma Laboratories, L.P., August 2013.</p>\n<p>2. Nordlund JR, Pasquale LR, Robin AL, et al, “The Cardiovascular, Pulmonary, and Ocular Hypotensive Effects of 0.2% Brimonidine,” <i>Arch Ophthalmol</i>, 1995, 113(1):77-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7826297\">[PubMed 7826297]</a></p>\n<p>3. Mungan NK, Wilson TW, Nischal KK, et al, “Hypotension and Bradycardia in Infants after the Use of Topical Brimonidine and Beta-Blockers,” <i>J AAPOS</i>, 2003, 7(1):69-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12690374\">[PubMed 12690374]</a></p>\n<p>4. Rangan C, Everson G, Cantrell FL, “Central Alpha-2 Adrenergic Eye Drops: Case Series of 3 Pediatric Systemic Poisonings,” <i>Pediatr Emerg Care</i>, 2008, 24(3):167-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18347496\">[PubMed 18347496]</a></p>\n<p>5. Berlin RJ, Lee UT, Samples JR, et al, “Ophthalmic Drops Causing Coma in an Infant,” <i>J Pediatr</i>, 2001, 138(3):441-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11241061\">[PubMed 11241061]</a></p>\n<p>6. Prescribing information. Alphagan P (brimonidine). Irvine, CA: Allergan, Inc., 5/2010.</p>\n<p>7. Enyedi LB, Freedman SF, “Safety and Efficacy of Brimonidine in Children with Glaucoma,” <i>J AAPOS</i>, 2001, 5(5):281-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11641636\">[PubMed 11641636]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7850":"<p><b>Title</b> Digoxin / Brimonidine (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Brimonidine (Topical) may enhance the bradycardic effect of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients extra closely for evidence of excessive response to digoxin therapy (e.g., bradycardia, etc.) when used with topical brimonidine.</p> \n<p><b>Discussion</b> The prescribing information for topical brimonidine cautions that concurrent use with cardiac glycosides may result in excessive systemic brimonidine effects such as hypotension, bradycardia, and/or CNS depression.<sup>1</sup><br><br>A study evaluating the cardiovascular effects of ophthalmic brimonidine, compared to ophthalmic timolol (0.5%) and betaxolol (0.25%) found that brimonidine reduced systolic blood pressure by 5.2 to 7.3 mmHg more than timolol or betaxolol (n=24 healthy volunteers).<sup>2</sup><br><br>One published report describes two infants who experienced bradycardia, hypotension, and CNS depression that was attributed to the concurrent use of ophthalmic brimonidine and a beta-blocker.<sup>3</sup> Though not specifically describing an interaction, other case reports describe systemic effects (unresponsiveness, altered mental status, hypotension, bradycardia) attributed to ophthalmic brimonidine when used in pediatric patients.<sup>4,5</sup> An analysis of 30 pediatric patients (mean age = 10.5 years) treated with ophthalmic brimonidine found that 7 patients (23%) experienced systemic effects ranging from fatigue to repeatedly being unarousable following brimonidine administration.<sup>6</sup><br><br>Of note, although use of topical brimonidine does appear to result in some systemic absorption, the prescribing information does not cite any reports of adverse effects consistent with bradycardia, hypotension, or CNS depression.<sup>1</sup><br><br>The likely mechanism for any such interaction is systemic alpha2-agonist actions of absorbed brimonidine leading to additive or synergistic bradycardic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Mirvaso (brimonidine). Fort Worth, TX: Galderma Laboratories, L.P., August 2013.</p>\n<p>2. Nordlund JR, Pasquale LR, Robin AL, et al, “The Cardiovascular, Pulmonary, and Ocular Hypotensive Effects of 0.2% Brimonidine,” <i>Arch Ophthalmol</i>, 1995, 113(1):77-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7826297\">[PubMed 7826297]</a></p>\n<p>3. Mungan NK, Wilson TW, Nischal KK, et al, “Hypotension and Bradycardia in Infants after the Use of Topical Brimonidine and Beta-Blockers,” <i>J AAPOS</i>, 2003, 7(1):69-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12690374\">[PubMed 12690374]</a></p>\n<p>4. Rangan C, Everson G, Cantrell FL, “Central Alpha-2 Adrenergic Eye Drops: Case Series of 3 Pediatric Systemic Poisonings,” <i>Pediatr Emerg Care</i>, 2008, 24(3):167-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18347496\">[PubMed 18347496]</a></p>\n<p>5. Berlin RJ, Lee UT, Samples JR, et al, “Ophthalmic Drops Causing Coma in an Infant,” <i>J Pediatr</i>, 2001, 138(3):441-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11241061\">[PubMed 11241061]</a></p>\n<p>6. Enyedi LB, Freedman SF, “Safety and Efficacy of Brimonidine in Children with Glaucoma,” <i>J AAPOS</i>, 2001, 5(5):281-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11641636\">[PubMed 11641636]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7851":"<p><b>Title</b> Brimonidine (Ophthalmic) / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Brimonidine (Ophthalmic). Monoamine Oxidase Inhibitors may increase the serum concentration of Brimonidine (Ophthalmic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of monoamine oxidase inhibitors (MAOIs) and ophthalmic brimonidine should only be undertaken with extra caution and monitoring as MAOIs may increase the risk for systemic adverse effects of brimonidine. If such concurrent use cannot be avoided, monitor patients closely for evidence of systemic toxicities such as hypotension, bradycardia, or CNS depression. Of note, the concomitant use of MAOIs with ophthalmic apraclonidine (another ophthalmic alpha2-agonist) is contraindicated.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> A risk of increased systemic alpha2-agonist effects is possible with concurrent use of monoamine oxidase inhibitors (MAOIs) and ophthalmic alpha2-agonists. The concomitant use of MAOIs and ophthalmic apraclonidine is contraindicated.<sup>1</sup> Although concurrent use with ophthalmic brimonidine is not specifically contraindicated, the brimonidine prescribing information does caution that MAOIs may increase the risk for systemic adverse effects.<sup>2</sup><br><br>Various case reports and post-marketing reports suggest ophthalmic alpha2-agonists are capable of causing systemic cardiovascular and central nervous system effects,<sup>1,2,3,4,5,6,7,8</sup> and it is suspected that MAOIs, which can independently cause significant cardiac and CNS effects and may alter the metabolism of the ophthalmic alpha2-agonists, can increase the risks for and severity of such effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Iopidine (apraclonidine). Fort Worth, TX: Alcon Laboratories, Inc., April 2004.</p>\n<p>2. Prescribing information. Alphagan P (brimonidine). Irvine, CA: Allergan, Inc., 5/2010.</p>\n<p>3. Pekdemir M, Yanturali S, Karakus G, “More than Just an Ocular Solution,” <i>Emerg Med J</i>, 2005, 22(10):753-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16189050\">[PubMed 16189050]</a></p>\n<p>4. Mungan NK, Wilson TW, Nischal KK, et al, “Hypotension and Bradycardia in Infants after the Use of Topical Brimonidine and Beta-Blockers,” <i>J AAPOS</i>, 2003, 7(1):69-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12690374\">[PubMed 12690374]</a></p>\n<p>5. Berlin RJ, Lee UT, Samples JR, et al, “Ophthalmic Drops Causing Coma in an Infant,” <i>J Pediatr</i>, 2001, 138(3):441-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11241061\">[PubMed 11241061]</a></p>\n<p>6. Nordlund JR, Pasquale LR, Robin AL, et al, “The Cardiovascular, Pulmonary, and Ocular Hypotensive Effects of 0.2% Brimonidine,” <i>Arch Ophthalmol</i>, 1995, 113(1):77-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7826297\">[PubMed 7826297]</a></p>\n<p>7. Rangan C, Everson G, Cantrell FL, “Central Alpha-2 Adrenergic Eye Drops: Case Series of 3 Pediatric Systemic Poisonings,” <i>Pediatr Emerg Care</i>, 2008, 24(3):167-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18347496\">[PubMed 18347496]</a></p>\n<p>8. Enyedi LB, Freedman SF, “Safety and Efficacy of Brimonidine in Children with Glaucoma,” <i>J AAPOS</i>, 2001, 5(5):281-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11641636\">[PubMed 11641636]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7852":"<p><b>Title</b> Apraclonidine / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Apraclonidine. Monoamine Oxidase Inhibitors may increase the serum concentration of Apraclonidine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of monoamine oxidase inhibitors (MAOIs) and ophthalmic apraclonidine is contraindicated. Although concurrent use with ophthalmic brimonidine is not specifically contraindicated, the brimonidine prescribing information does caution that MAOIs may increase the risk for systemic adverse effects. If such concurrent use cannot be avoided, monitor patients closely for evidence of systemic toxicities such as hypotension, bradycardia, or CNS depression.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> A risk of increased systemic alpha2-agonist effects is possible with concurrent use of monoamine oxidase inhibitors (MAOIs) and ophthalmic alpha2-agonists. The concomitant use of MAOIs and ophthalmic apraclonidine is contraindicated.<sup>1</sup> Although concurrent use with ophthalmic brimonidine is not specifically contraindicated, the brimonidine prescribing information does caution that MAOIs may increase the risk for systemic adverse effects.<sup>2</sup><br><br>Various case reports and post-marketing reports suggest ophthalmic alpha2-agonists are capable of causing systemic cardiovascular and central nervous system effects,<sup>1,2,3,4,5,6,7,8</sup> and it is suspected that MAOIs, which can independently cause significant cardiac and CNS effects and may alter the metabolism of the ophthalmic alpha2-agonists, can increase the risks for and severity of such effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Iopidine (apraclonidine). Fort Worth, TX: Alcon Laboratories, Inc., April 2004.</p>\n<p>2. Prescribing information. Alphagan P (brimonidine). Irvine, CA: Allergan, Inc., 5/2010.</p>\n<p>3. Pekdemir M, Yanturali S, Karakus G, “More than Just an Ocular Solution,” <i>Emerg Med J</i>, 2005, 22(10):753-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16189050\">[PubMed 16189050]</a></p>\n<p>4. Mungan NK, Wilson TW, Nischal KK, et al, “Hypotension and Bradycardia in Infants after the Use of Topical Brimonidine and Beta-Blockers,” <i>J AAPOS</i>, 2003, 7(1):69-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12690374\">[PubMed 12690374]</a></p>\n<p>5. Berlin RJ, Lee UT, Samples JR, et al, “Ophthalmic Drops Causing Coma in an Infant,” <i>J Pediatr</i>, 2001, 138(3):441-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11241061\">[PubMed 11241061]</a></p>\n<p>6. Nordlund JR, Pasquale LR, Robin AL, et al, “The Cardiovascular, Pulmonary, and Ocular Hypotensive Effects of 0.2% Brimonidine,” <i>Arch Ophthalmol</i>, 1995, 113(1):77-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7826297\">[PubMed 7826297]</a></p>\n<p>7. Rangan C, Everson G, Cantrell FL, “Central Alpha-2 Adrenergic Eye Drops: Case Series of 3 Pediatric Systemic Poisonings,” <i>Pediatr Emerg Care</i>, 2008, 24(3):167-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18347496\">[PubMed 18347496]</a></p>\n<p>8. Enyedi LB, Freedman SF, “Safety and Efficacy of Brimonidine in Children with Glaucoma,” <i>J AAPOS</i>, 2001, 5(5):281-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11641636\">[PubMed 11641636]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7862":"<p><b>Title</b> Anticoagulants / Sugammadex</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sugammadex may enhance the anticoagulant effect of Anticoagulants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients extra closely for signs/symptoms of bleeding (including monitoring of INR and/or aPTT, etc.) when using sugammadex in a patient who is also being treated with an anticoagulant. Patients receiving higher-dose sugammadex, those with higher INR goals, and patients with other risk factors for bleeding are likely at higher risk for a potentially significant interaction.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> According to the sugammadex summary of product characteristics, sugammadex treatment (4 mg/kg and 16 mg/kg doses) was associated with an 11-22% average increase in prothrombin time (PT) and a 17-22% average increase in activated partial thromboplastin time (aPTT).<sup>1,2</sup> These increases were noted to be of relatively short duration, lasting 30 minutes or less. There was no evidence of increased bleeding from clinical trial data (n=1,738) and data from a specific study in patients having hip fracture or major joint repair surgery (n=1,184) receiving sugammadex (4 mg/kg dose) alone or with concurrent anticoagulants.<br><br>The mechanism for this potential interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of Product Characteristics. Bridion (sugammadex). Oss, The Netherlands: N.V. Organon, July 2013.</p>\n<p>2. Summary of Product Characteristics (Singapore). Bridion (sugammadex). Whitehouse Station, NJ: Merck &amp; Co., Inc., May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7863":"<p><b>Title</b> Progestins (Contraceptive) / Sugammadex</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sugammadex may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving any hormonal contraceptive (oral or non-oral) should use an additional, nonhormonal contraceptive method during and for 7 days following sugammadex treatment.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Sugammadex US and international product labeling states that it may decrease the effectiveness of hormonal contraceptives.<sup>1,2,3,4</sup> Binding studies suggest that sugammadex may bind to progestogen, and receiving sugammadex on the same day as an oral progestin- and/or estrogen-containing contraceptive should be viewed as equivalent to missing contraceptive doses on those days.<sup>1</sup> The use of sugammadex at a 4 mg/kg dose is expected to decrease progestin exposure by an average of 34%.<sup>2,3,4</sup><br><br>The suspected primary mechanism of interaction between these agents is sugammadex binding to progestins, decreasing free and/or total progestin exposure.<sup>1,2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bridion (sugammadex) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; December 2015. </p>\n<p>2. Bridion (sugammadex) [summary of product characteristics]. Oss, The Netherlands: NV Organon; July 2013.</p>\n<p>3. Bridion (sugammadex) [Singapore summary of product characteristics]. Whitehouse Station, NJ: Merck &amp; Co Inc; May 2013.</p>\n<p>4. Bridion (sugammadex) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7864":"<p><b>Title</b> Sugammadex / Toremifene</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Toremifene may diminish the therapeutic effect of Sugammadex. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient response to sugammadex extra closely if that patient has taken toremifene that same day, and note that response to sugammadex may be delayed. Also monitor closely for signs/symptoms of recurrent neuromuscular blockade in these patients.</p> \n<p><b>Discussion</b> Sugammadex US and international product labeling states that the use of drugs that can displace vecuronium or rocuronium from their complex with sugammadex may decrease the effectiveness of sugammadex treatment.<sup>1,2,3,4</sup> Patients receiving toremifene on the same day as sugammadex may experience a delayed recovery. Also, since it is noted that displacing agents may also increase the risk for recurrence of neuromuscular blockade (though this seems to be mostly a concern with intravenous administration within 7.5 hours of sugammadex use), close monitoring for recurrent neuromuscular blockade may also be warranted in patients who have taken toremifene the same day as sugammadex.<sup>1,2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bridion (sugammadex) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; December 2015. </p>\n<p>2. Bridion (sugammadex) [summary of product characteristics]. Oss, The Netherlands: NV Organon; July 2013.</p>\n<p>3. Bridion (sugammadex) [Singapore summary of product characteristics]. Whitehouse Station, NJ: Merck &amp; Co Inc; May 2013.</p>\n<p>4. Bridion (sugammadex) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; February 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7865":"<p><b>Title</b> Citalopram / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Citalopram. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The efficacy of citalopram may be significantly reduced with concurrent use of rifampin. Monitor patients using this combination closely for evidence of reduced citalopram effectiveness. Consider use of an alternative agent to rifampin if possible. It is unclear if other selective serotonin reuptake inhibitors (SSRIs) would have a lower risk of interacting with rifampin.</p> \n<p><b>Discussion</b> A case report describes a 27-year-old female who was started on rifampin 600 mg/day and doxycycline 100 mg twice/day for treatment of brucellosis.<sup>1</sup> The patient’s past medical history was significant only for a 2-year use of citalopram 20 mg daily to treat panic attacks. After 5 days of treatment for brucellosis, the patient developed anxiety, agitation, tachycardia, dyspepsia, nausea, and abdominal pain. It was determined that her symptoms were consistent with recurrent panic attacks, and she was started on propranolol 20 mg twice daily, with her citalopram later increased to 40 mg daily. Her symptoms improved, and propranolol was tapered off.<br><br>In another case report, a 55-year-old male with osteomyelitis was treated with rifampin 600 mg once daily and sulfamethoxazole/trimethoprim double-strength twice daily.<sup>2</sup> The patient’s medical history included the use of citalopram 40 mg once daily and clonazepam 1 mg twice daily. After a month of treatment, the patient complained of gastrointestinal symptoms and was advised to discontinue use of the antibiotics; however, he continued to take rifampin. He then reported increased incidences of panic attacks and crying, so his psychiatrist increased his clonazepam to 5 mg daily, and later, changed citalopram to escitalopram under the incorrect assumption that escitalopram was not susceptible to CYP2C19/CYP3A4 induction. Two weeks later, the use of rifampin was discovered and discontinued, and the patient was switched back to citalopram 60 mg daily and clonazepam 1 mg twice daily. The patient’s reported anxiety and crying symptoms significantly decreased within a few weeks.<br><br>The likely mechanism for this interaction is a rifampin-mediated increase in the metabolism of citalopram, leading to decreased citalopram concentrations and effects. Citalopram is extensively metabolized primarily through CYP3A4 and CYP2C19. Rifampin is a strong inducer of several cytochrome P450 enzymes, including CYP2C19 and CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Khalili H, Dashti-Khavidaki S, Amini S, et al, “Recurrence of Panic Attacks after Brucellosis Treatment--Highly Probable Citalopram and Rifampin Drug Interaction,” <i>J Clin Psychopharmacol</i>, 2012, 32(6):842-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23131874\">[PubMed 23131874]</a></p>\n<p>2. Kukoyi O, Argo TR, Carnahan RM, “Exacerbation of Panic Disorder with Rifampin Therapy in a Patient Receiving Citalopram,” <i>Pharmacotherapy</i>, 2005, 25(3):435-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15843291\">[PubMed 15843291]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7866":"<p><b>Title</b> Warfarin / Miconazole (Oral)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Miconazole (Oral) may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor extra closely for increased warfarin response (i.e., INR, signs/symptoms of bleeding, etc.) if a patient maintained on warfarin begins therapy with oral miconazole. Rapid and dramatic increases in INR and/or appearance of bleeding has been reported with this combination, despite the fact that oral miconazole is generally considered nonabsorbed.</p> \n<p><b>Discussion</b> Oral miconazole is currently available as a buccal tablet, but most available data concerning oral miconazole are with an oral gel. The prescribing information for the oral buccal tablet does, however, caution that oral miconazole may increase the anticoagulant effect of warfarin.<sup>1</sup><br><br>A retrospective analysis of 32 anticoagulated patients who were treated with oral miconazole gel found that 15 (47%) patients experienced bleeding episodes, and that the mean INR increased from 2.4 to 8.8 following initiation of oral miconazole.<sup>2</sup> The mean weekly warfarin dose requirement decreased from 15.7 mg to 10.8 mg (31% decrease).<br><br>Many case reports similarly describe patients who experienced bleeding and/or a significant increase in INR associated with the initiation of oral miconazole gel.<sup>3,4,5,6,7,8,9,10,11,12</sup><br><br>The mechanism for this apparent interaction is likely miconazole-mediated inhibition of the CYP2C9-mediated metabolism of the more potent S-warfarin, with some possible contribution of inhibition of the CYP2C19- and/or CYP3A-mediated metabolism of the less potent R-warfarin, as miconazole has been shown to be a highly potent inhibitor of CYP2C9 and CYP2C19 and a somewhat less potent inhibitor of CYP3A.<sup>13</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Oravig (miconazole). Cary, NC: Praelia Pharmaceuticals, Inc., 08/2012.</p>\n<p>2. Kovac M, Mitic G, Kovac Z, “Miconazole and Nystatin Used as Topical Antifungal Drugs Interact Equally Strongly with Warfarin,” <i>J Clin Pharm Ther</i>, 2012, 37(1):45-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21332566\">[PubMed 21332566]</a></p>\n<p>3. Ufondu CC, Ferrins P, Cushen A, et al, “Warfarin and Topical Miconazole: The Potential for a Clinically Significant Interaction,” <i>Ir J Med Sci</i>, 2013, 182(1):153-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23115023\">[PubMed 23115023]</a></p>\n<p>4. Broos N, van Puijenbroek EP, “Interaction between Topical Miconazole and Coumarins,” <i>Eur J Clin Pharmacol</i>, 2010, 66(11):1171-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20658342\">[PubMed 20658342]</a></p>\n<p>5. Devaraj A, O'Beirne JP, Veasey R, et al, “Interaction between Warfarin and Topical Miconazole Cream,” <i>BMJ</i>, 2002, 325(7355):77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12114237\">[PubMed 12114237]</a></p>\n<p>6. Murty M, “Miconazole-Warfarin Interaction: Increased INR,” <i>CMAJ</i>, 2001, 165(1):81-2, 85-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11468962\">[PubMed 11468962]</a></p>\n<p>7. Silingardi M, Ghirarduzzi A, Tincani E, et al, “Miconazole Oral Gel Potentiates Warfarin Anticoagulant Activity,” <i>Thromb Haemost</i>, 2000, 83(5):794-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10823285\">[PubMed 10823285]</a></p>\n<p>8. Pemberton MN, Sloan P, Ariyaratnam S, et al, “Derangement of Warfarin Anticoagulation by Miconazole Oral Gel,” <i>Br Dent J</i>, 1998, 184(2):68-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9489213\">[PubMed 9489213]</a></p>\n<p>9. Ariyaratnam S, Thakker NS, Sloan P, et al, “Potentiation of Warfarin Anticoagulant Activity by Miconazole Oral Gel,” <i>BMJ</i>, 1997, 314(7077):349. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9040331\">[PubMed 9040331]</a></p>\n<p>10. Pillans P, Woods DJ, “Interaction between Miconazole Oral Gel (Daktarin) and Warfarin,” <i>N Z Med J</i>, 1996, 109(1029):346. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8862358\">[PubMed 8862358]</a></p>\n<p>11. Shenfield GM, Page M, “Potentiation of Warfarin Action by Miconazole Oral Gel,” <i>Aust N Z J Med</i>, 1991, 21(6):928. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1818557\">[PubMed 1818557]</a></p>\n<p>12. Colquhoun MC, Daly M, Stewart P, et al, “Interaction between Warfarin and Miconazole Oral Gel,” <i>Lancet</i>, 1987, 1(8534):695-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2882124\">[PubMed 2882124]</a></p>\n<p>13. Niwa T, Shiraga T, Takagi A, “Effect of Antifungal Drugs on Cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 Activities in Human Liver Microsomes,” <i>Biol Pharm Bull</i>, 2005, 28(9):1805-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16141567\">[PubMed 16141567]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7867":"<p><b>Title</b> Escitalopram / Miconazole (Oral)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Miconazole (Oral) may increase the serum concentration of Escitalopram. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor patients for excessive response to escitalopram when patients also use oral miconazole. Despite the characterization of oral miconazole as generally nonabsorbed, several systemic drug interactions have been reported with oral miconazole.</p> \n<p><b>Discussion</b> A case report describes an 88-year-old female receiving escitalopram who experienced serotonin syndrome following the initiation of oral miconazole (mucoadhesive tablet).<sup>1</sup><br><br>Though oral miconazole is generally considered nonabsorbed, the prescribing information does warn that systemic drug interactions are possible, with emphasis on CYP2C9- and CYP3A-metabolized drugs, and a specific caution concerning concurrent warfarin.<sup>2</sup> Thus, the likely mechanism for this reported interaction is miconazole-mediated inhibition of the CYP2C19- and/or CYP3A-mediated metabolism of escitalopram, as miconazole has been shown to be a highly potent inhibitor of CYP2C9 and CYP2C19 and a somewhat less potent inhibitor of CYP3A.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Baptista G, Eiden C, Monguillot P, et al, “Serotonin Syndrome during Treatment with Low Dose of Escitalopram Associated with Miconazole Mucoadhesive Tablet: A Suspected Drug Interaction,” <i>Int Psychogeriatr</i>, 2012, 24(5):845-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22251853\">[PubMed 22251853]</a></p>\n<p>2. Prescribing information. Oravig (miconazole). Cary, NC: Praelia Pharmaceuticals, Inc., 08/2012.</p>\n<p>3. Niwa T, Shiraga T, Takagi A, “Effect of Antifungal Drugs on Cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 Activities in Human Liver Microsomes,” <i>Biol Pharm Bull</i>, 2005, 28(9):1805-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16141567\">[PubMed 16141567]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7868":"<p><b>Title</b> OxyCODONE / Miconazole (Oral)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Miconazole (Oral) may decrease serum concentrations of the active metabolite(s) of OxyCODONE. Miconazole (Oral) may increase the serum concentration of OxyCODONE. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action needed.</p> \n<p><b>Discussion</b> The average oxycodone AUC increased by 63%, but the average AUC of the active metabolite oxymorphone was reduced by 83%, when oxycodone (10 mg immediate-release x1) was given to 12 healthy volunteers who were also receiving miconazole oral gel (85 mg three times/day).<sup>1</sup> No significant changes in response to oxycodone were noted, and the authors concluded that this interaction is likely to be of no more than moderate clinical relevance. Of note, the currently available oral miconazole product is a mucoadhesive buccal tablet, which is dosed at 50 mg once/day, calling into question whether the same magnitude of effect observed in this study (with 85 mg three times/day of oral gel) would be seen with this formulation and/or at this dose. Further, the general balance observed between the active oxycodone and oxymorphone entities (i.e., concentration of one increased while concentration of the other decreased) supports the general lack of observed pharmacodynamic effects and the prediction of a relatively low-to-moderate clinical significance.<br><br>Though oral miconazole is generally considered nonabsorbed, the prescribing information does warn that systemic drug interactions are possible, with emphasis on CYP2C9- and CYP3A-metabolized drugs, and a specific caution concerning concurrent warfarin.<sup>2</sup> Thus, the likely mechanism for this reported interaction is miconazole-mediated inhibition of the CYP2D6-mediated metabolism of oxycodone to oxymorphone, as miconazole has been shown to be a highly potent inhibitor of CYP2D6.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gronlund J, Saari TI, Hagelberg N, et al, “Miconazole Oral Gel Increases Exposure to Oral Oxycodone by Inhibition of CYP2D6 and CYP3A4,” <i>Antimicrob Agents Chemother</i>, 2011, 55(3):1063-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21173180\">[PubMed 21173180]</a></p>\n<p>2. Prescribing information. Oravig (miconazole). Cary, NC: Praelia Pharmaceuticals, Inc., 08/2012.</p>\n<p>3. Niwa T, Inoue-Yamamoto S, Shiraga T, et al, “Effect of Antifungal Drugs on Cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 Activities in Human Liver Microsomes,” <i>Biol Pharm Bull</i>, 2005, 28(9):1813-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16141569\">[PubMed 16141569]</a></p>\n<p>4. Zhang W, Ramamoorthy Y, Kilicarslan T, et al, “Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives,” <i>Drug Metab Dispos</i>, 2002, 30(3):314-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11854151\">[PubMed 11854151]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7869":"<p><b>Title</b> Digoxin / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Digoxin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Ketoconazole prescribing information warns that rare cases of elevated digoxin concentrations have been reported during ketoconazole treatment.<sup>1</sup> <br><br>In a study of 10 healthy subjects, pretreatment with 4 days of 200 mg ketoconazole orally daily resulted in a nonsignificant 9% average increase in drug exposure from a single 0.5 mg dose of digoxin compared to placebo.<sup>2</sup><br><br>Ketoconazole could theoretically inhibit p-glycoprotein mediated digoxin transport. <i>In vitro</i> data support this as a potential mechanism for interaction.<sup>3</sup> In contrast to results seen with itraconazole, however, increases in digoxin exposure with ketoconazole appear to be mild. CYP3A4 inhibition of digoxin metabolism by ketoconazole would be expected to play a small role in an interaction, if any, given the minor contribution of this pathway to digoxin elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Nizoral (ketoconazole). Titusville, NJ: Janssen Pharmaceutical Products, L.P., February 2002.</p>\n<p>2. Larsen UL, Olesen L, Guldborg Nyvold C, et al, “Human Intestinal P-Glycoprotein Activity Estimated by the Model Substrate Digoxin,” <i>Scand J Clin Lab Invest</i>, 2007, 67(2):123-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17365992\">[PubMed 17365992]</a></p>\n<p>3. Kim RB, Wandel C, Leake B, et al, “Relationship between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein,” <i>Pharm Res</i>, 1999, 16(3):408-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10213372\">[PubMed 10213372]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7870":"<p><b>Title</b> Tacrolimus (Systemic) / Maraviroc</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Maraviroc may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A case report describes a patient who experienced an approximate 21% increase in tacrolimus AUC following initiation of maraviroc.<sup>1</sup> Despite this increase, the patient's tacrolimus AUC was still reportedly in the therapeutic range, and no adverse effect of this increase was noted. Also, the patient's maraviroc trough concentration (i.e., Cmin) was higher than the recommended level. Whether this is related to the concurrent use of tacrolimus is unknown.<br><br>The mechanism(s) for this reported interaction is uncertain. However, since both tacrolimus and maraviroc are CYP3A4 substrates (tacrolimus is also considered a weak CYP3A4 inhibitor), competition for CYP3A-mediated metabolism could be at least partially responsible for the observed increase in tacrolimus concentrations and possible increase in maraviroc concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dufty NE, Gilleran G, Hawkins D, et al, “Pharmacokinetic Interaction of Maraviroc with Tacrolimus in a Patient Coinfected with HIV and Hepatitis B Virus following Hepatic Transplant Due to Hepatocellular Carcinoma,” <i>J Antimicrob Chemother</i>, 2013, 68(4):972-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23249840\">[PubMed 23249840]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7871":"<p><b>Title</b> Acenocoumarol / Green Tea</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Green Tea may enhance the adverse/toxic effect of Acenocoumarol. Particularly, the risk of bleeding may be increased due to possible antiplatelet effects of green tea. Green Tea may diminish the anticoagulant effect of Acenocoumarol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients to report green tea consumption, and monitor acenocoumarol response particularly closely in those patients who regularly consume green tea (especially larger quantities) and in those patients who have recently started or stopped consuming green tea.</p> \n<p><b>Discussion</b> One patient who was being treated with warfarin experienced a substantial decrease in his INR (from 3.2-3.8 to 1.1-1.4) that roughly coincided with his newly regular consumption of 1/2 to 1 gallon/day of green tea.<sup>1</sup> Though green tea leaves reportedly contain approximately 5-fold more vitamin K than black tea (1428mcg vs. 262mcg per 100g leaves),<sup>2,3</sup> the vitamin K content of brewed green tea is relatively low (0.03mcg/100g brewed tea), but may vary according to strength and brewing methods.<sup>4</sup><br><br>Conversely, animal and in vitro data suggest that green tea constituents may have antiplatelet properties.<sup>5</sup> Also, epidemiologic studies have found evidence of an inverse association between green tea consumption and the risk of stroke,<sup>6,7</sup> providing possible additional support for an antiplatelet effect of green tea.<br><br>Based on this relatively limited amount of data, it is difficult to predict the degree to which green tea consumption would impact vitamin K antagonist (or other anticoagulant/antiplatelet) therapy, as well as whether the impact would be antagonistic or additive/synergistic. However, it would seem prudent to advise patients to report green tea consumption and monitor vitamin K antagonist response particularly closely in those patients who regularly consume green tea (especially larger quantities) and in those patients who have recently started or stopped consuming green tea.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Taylor JR, Wilt VM, “Probable Antagonism of Warfarin by Green Tea,” <i>Ann Pharmacother</i>, 1999, 33(4):426-8.</p>\n<p>2. Booth SL, Sadowski JA, Pennington JAT, “Phylloquinone (Vitamin K1) Content of Foods in the US Food and Drug Administration’s Total Diet Study,” <i>J Agric Food Chem</i>, 1995, 43:1574-9.</p>\n<p>3. Booth SL, Sadowski JA, Pennington JAT, “Vitamin K1 (Phylloquinone) Content of Foods: a Provisional Table,” <i>J Food Comp Anal</i>, 1993, 6:109-20.</p>\n<p>4. Booth SL, Madabushi HT, Davidson KW, “Tea and Coffee Brews are Not Significant Dietary Sources of Vitamin K1 (Phylloquinone),” <i>J Am Diet Assoc</i>, 1995, 95:82-3.</p>\n<p>5. Kang WS, Lim IH, Yuk DY, et al, “Antithrombotic Activities of Green Tea Catechins and (-)-Epigallocatechin Gallate,” <i>Thromb Res</i>, 1999, 96:229-37.</p>\n<p>6. Sato Y, Nakatsuka H, Watanabe T, et al, “Possible Contribution of Green Tea Drinking Habits to the Prevention of Stroke,” <i>Tohoku J Exp Med</i>, 1989, 157:337-43.</p>\n<p>7. Tanabe N, Suzuki H, Aizawa Y, et al, “Consumption of Green and Roasted Teas and the Risk of Stroke Incidence: Results from the Tokamachi-Nakasato Cohort Study in Japan,” <i>Int J Epidemiol</i>, 2008, 37:1030-40.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7872":"<p><b>Title</b> Warfarin / Green Tea</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Green Tea may enhance the adverse/toxic effect of Warfarin. Particularly, the risk of bleeding may be increased due to possible antiplatelet effects of green tea. Green Tea may diminish the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients to report green tea consumption, and monitor warfarin response particularly closely in those patients who regularly consume green tea (especially larger quantities) and in those patients who have recently started or stopped consuming green tea.</p> \n<p><b>Discussion</b> One patient who was being treated with warfarin experienced a substantial decrease in his INR (from 3.2-3.8 to 1.1-1.4) that roughly coincided with his newly regular consumption of 1/2 to 1 gallon/day of green tea.<sup>1</sup> Though green tea leaves reportedly contain approximately 5-fold more vitamin K than black tea (1428mcg vs. 262mcg per 100g leaves),<sup>2,3</sup> the vitamin K content of brewed green tea is relatively low (0.03mcg/100g brewed tea), but may vary according to strength and brewing methods.<sup>4</sup><br><br>Conversely, animal and in vitro data suggest that green tea constituents may have antiplatelet properties.<sup>5</sup> Also, epidemiologic studies have found evidence of an inverse association between green tea consumption and the risk of stroke,<sup>6,7</sup> providing possible additional support for an antiplatelet effect of green tea.<br><br>Based on this relatively limited amount of data, it is difficult to predict the degree to which green tea consumption would impact vitamin K antagonist (or other anticoagulant/antiplatelet) therapy, as well as whether the impact would be antagonistic or additive/synergistic. However, it would seem prudent to advise patients to report green tea consumption and monitor vitamin K antagonist response particularly closely in those patients who regularly consume green tea (especially larger quantities) and in those patients who have recently started or stopped consuming green tea.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Taylor JR, Wilt VM, “Probable Antagonism of Warfarin by Green Tea,” <i>Ann Pharmacother</i>, 1999, 33(4):426-8.</p>\n<p>2. Booth SL, Sadowski JA, Pennington JAT, “Phylloquinone (Vitamin K1) Content of Foods in the US Food and Drug Administration’s Total Diet Study,” <i>J Agric Food Chem</i>, 1995, 43:1574-9.</p>\n<p>3. Booth SL, Sadowski JA, Pennington JAT, “Vitamin K1 (Phylloquinone) Content of Foods: a Provisional Table,” <i>J Food Comp Anal</i>, 1993, 6:109-20.</p>\n<p>4. Booth SL, Madabushi HT, Davidson KW, “Tea and Coffee Brews are Not Significant Dietary Sources of Vitamin K1 (Phylloquinone),” <i>J Am Diet Assoc</i>, 1995, 95:82-3.</p>\n<p>5. Kang WS, Lim IH, Yuk DY, et al, “Antithrombotic Activities of Green Tea Catechins and (-)-Epigallocatechin Gallate,” <i>Thromb Res</i>, 1999, 96:229-37.</p>\n<p>6. Sato Y, Nakatsuka H, Watanabe T, et al, “Possible Contribution of Green Tea Drinking Habits to the Prevention of Stroke,” <i>Tohoku J Exp Med</i>, 1989, 157:337-43.</p>\n<p>7. Tanabe N, Suzuki H, Aizawa Y, et al, “Consumption of Green and Roasted Teas and the Risk of Stroke Incidence: Results from the Tokamachi-Nakasato Cohort Study in Japan,” <i>Int J Epidemiol</i>, 2008, 37:1030-40.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7873":"<p><b>Title</b> Digoxin / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Voriconazole does not appear to affect serum concentration of Digoxin. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A study of 25 healthy volunteers detected no difference in steady state pharmacokinetic variables (including maximum plasma concentration, AUC, and minimum concentration) of digoxin 0.25 mg orally daily with coadministration of voriconazole 200 mg orally twice daily.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Purkins L, Wood N, Kleinermans D, et al, “Voriconazole does not Affect the Steady-State Pharmacokinetics of Digoxin,” <i>Br J Clin Pharmacol,</i> 2003, 56 Suppl 1:45-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616413\">[PubMed 14616413]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7874":"<p><b>Title</b> Digoxin / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Posaconazole may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased digoxin concentrations/effects when combined with posaconazole.</p> \n<p><b>Discussion</b> Prescribing information for posaconazole recommends monitoring of serum digoxin concentrations during posaconazole treatment, based on reports of elevated digoxin concentrations during concomitant therapy.<sup>1</sup><br><br>The mechanism of any interaction between these drugs is unknown. It is unknown whether posaconazole inhibits activity of P-glycoprotein, a transporter of digoxin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Noxafil (posaconazole) [prescribing information]. Kenilworth, NJ: Schering Corporation; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7875":"<p><b>Title</b> Theophylline Derivatives / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for increased theophylline systemic concentrations and effects in patients treated with estrogen derivatives.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline<br><b>Exception</b> Dyphylline</p>\n</div> \n<p><b>Discussion</b> In a clinical study of healthy volunteers, the estimated theophylline clearance when a single dose of aminophylline (4 mg/kg orally) was given 1 hour after an oral contraceptive dose was around 50% lower in 8 individuals treated chronically (over 6 months) with an oral contraceptive compared to 8 individuals not treated chronically with an oral contraceptive.<sup>1</sup> A subsequent study by the same investigators identified a smaller (roughly 30%) average lower theophylline clearance in oral contraceptive users.<sup>2</sup> In a third study, however, theophylline clearance following a single intravenous aminophylline dose (7.6 mg/kg) was no different between adolescent females treated with an oral contraceptive versus those not treated with an oral contraceptive.<sup>3</sup><br><br>The mechanism of this possible interaction has not been studied, but may involve inhibition of CYP1A2 mediated theophylline metabolism by estrogen derivatives. Data indicating a decrease in the caffeine metabolic ratio during estradiol hormone replacement therapy also support this hypothesis.<sup>4</sup> The reasons for the disparate study findings cited above are not clear; these could derive from differences in the specific contraceptive products used, the populations under study, the routes of theophylline administration, or other factors. U.S. drug labeling for theophylline warns about the potential for estrogen to decrease theophylline clearance in a dose-dependent manner, specifically referring to use with estrogen containing combined oral contraceptives.<sup>5</sup> Some oral contraceptive products warn about this risk as well,<sup>6</sup> as does international labeling for some estrogen derivative containing hormone replacement products.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tornatore KM, Kanarkowski R, McCarthy TL, et al, “Effect of Chronic Oral Contraceptive Steroids on Theophylline Disposition,” <i>Eur J Clin Pharmacol</i>, 1982, 23(2):129-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7140802\">[PubMed 7140802]</a></p>\n<p>2. Gardner MJ, Tornatore KM, Jusko WJ, “Effects of Tobacco Smoking and Oral Contraceptive Use on Theophylline Disposition,” <i>Br J Clin Pharmacol</i>, 1983, 16(3):271-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6626419\">[PubMed 6626419]</a></p>\n<p>3. Koren G, Chin TF, Correia J, et al, “Theophylline Pharmacokinetics in Adolescent Females Following Coadministration of Oral Contraceptives,” <i>Clin Invest Med</i>, 1985, 8(3):222-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4042465\">[PubMed 4042465]</a></p>\n<p>4. Pollock BG, Wylie M, Stack JA, et al, “Inhibition of Caffeine Metabolism by Estrogen Replacement Therapy in Postmenopausal Women,” <i>J Clin Pharmacol</i>, 1999, 39(9):936-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10471985\">[PubMed 10471985]</a></p>\n<p>5. Prescribing information. Theo-24 (theophylline). Smyrna, GA: UCB Pharma, Inc., 4/2005.</p>\n<p>6. Prescribing information. Altavera (theophylline). Princeton, NJ: Sandoz Inc., August 2010.</p>\n<p>7. Product information. Femoston (estradiol and dydrogesterone). Botany NSW, Australia: Abbott Australasia Pty Ltd, November 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7876":"<p><b>Title</b> Repaglinide / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: The addition of a CYP2C8 inhibitor to this drug combination may substantially increase the magnitude of increase in repaglinide exposure.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Repaglinide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased hypoglycemic response to repaglinide when used in combination with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The effect of strong CYP3A4 inhibitors on repaglinide pharmacokinetics has been evaluated in several studies.<sup>1,2,3,4,5</sup> The repaglinide AUC increased 77% when coadministered with telithromycin (800 mg daily for 3 days),<sup>1</sup> 40% when coadministered with clarithromycin (250 mg twice daily for 4 days),<sup>2</sup> 40% when coadministered with itraconazole (100 mg daily),<sup>3,4</sup> and 15% when coadministered with ketoconazole (200 mg daily).<sup>5</sup> In one study the mean serum insulin AUC was increased approximately 50% when repaglinide was combined with clarithromycin.<sup>2</sup> In support of these studies, a case report describes an 80-year old male taking repaglinide for years who experienced 2 episodes of severe hypoglycemia after initiation of clarithromycin therapy.<sup>6</sup><br><br>The suspected mechanism of the above interactions is inhibition of CYP3A4-mediated repaglinide metabolism by strong CYP3A4 inhibitors. However, because CYP3A4 and CYP2C8 are the primary pathways of repaglinide metabolism,<sup>4</sup> the use of repaglinide with a strong CYP3A4 and a CYP2C8 inhibitor may result in a more significant interaction. Coadministration of the CYP2C8 inhibitor gemfibrozil increased the repaglinide AUC 8.1-fold and the combination of gemfibrozil and itraconazole increased the repaglinide AUC 19.4-fold.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kajosaari LI, Niemi M, Backman JT, Neuvonen PJ. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. <i>Clin Pharmacol Ther</i>. 2006;79(3):231-242 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16513447\">[PubMed 16513447]</a></p>\n<p>2. Niemi M, Neuvonen PJ, Kivisto KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. <i>Clin Pharmacol Ther</i>. 2001;70(1):58-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11452245\">[PubMed 11452245]</a></p>\n<p>3. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. <i>Diabetologia</i>. 2003;46(3):347-351. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12687332\">[PubMed 12687332]</a></p>\n<p>4. Prandin (repaglinide) [prescribing information]. Princeton, NJ: Novo Nordisk Pharmaceuticals Inc; 2017.</p>\n<p>5. Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. <i>J Clin Pharmacol</i>. 2003;43(6):649-660. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12817528\">[PubMed 12817528]</a></p>\n<p>6. Khamaisi M, Leitersdorf E. Severe hypoglycemia from clarithromycin-repaglinide drug interaction. <i>Pharmacotherapy</i>. 2008;28(5):682-684. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18447665\">[PubMed 18447665]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7877":"<p><b>Title</b> Digoxin / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Grapefruit Juice does not appear to affect serum concentration of Digoxin. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Concomitant administration of grapefruit juice and digoxin (0.5 mg single oral dose) did not appreciably affect C<sub>max</sub> or AUC of digoxin in 12 healthy subjects.<sup>1</sup> Similarly, concomitant administration of grapefruit juice and digoxin (1 mg single oral dose) did not affect digoxin AUC in 7 healthy subjects, although digoxin absorption was delayed.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Becquemont L, Verstuyft C, Kerb R, et al, “Effect of Grapefruit Juice on Digoxin Pharmacokinetics in Humans,” <i>Clin Pharmacol Ther</i>, 2001, 70(4):311-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11673746\">[PubMed 11673746]</a></p>\n<p>2. Parker RB, Yates CR, Soberman JE, et al, “Effects of Grapefruit Juice on Intestinal P-glycoprotein: Evaluation Using Digoxin in Humans,” <i>Pharmacotherapy</i>, 2003, 23(8):979-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12921244\">[PubMed 12921244]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7878":"<p><b>Title</b> Digoxin / Nefazodone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nefazodone may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects and/or serum concentrations of cardiac glycosides if nefazodone is initiated/dose increased, or decreased effects/concentrations if nefazodone is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC of digoxin (0.2 mg/day) was increased by an average of 15% when coadministered with nefazodone (200 mg twice daily) for 8 days in a study of healthy volunteers (n=18).<sup>1</sup> Both maximum (Cmax) and minimum (Cmin) serum digoxin concentrations were also increased (by 29% and 27%, respectively). No differences in clinical digoxin effects were noted. The mechanism of this interaction is unknown, but the nefazodone prescribing information recommends caution and increased digoxin monitoring when this combination is used.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dockens RC, Greene DS, and Barbhaiya RH, “Assessment of Pharmacokinetic and Pharmacodynamic Drug Interactions Between Nefazodone and Digoxin in Healthy Male Volunteers,” <i>J Clin Pharmacol</i>, 1996, 36:160-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8852392\">[PubMed 8852392]</a></p>\n<p>2. Prescribing information. Serzone (nefazodone). Princeton, NJ: Bristol-Myers Squibb Company, January 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7879":"<p><b>Title</b> Digoxin / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations/therapeutic effects of cardiac glycosides if St Johns Wort is initiated/dose increased, or increased serum concentrations/effects if St Johns Wort is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The AUC of digoxin (0.25 mg/day) was decreased by 28% in healthy subjects when coadministered with hypericum extract (containing 92 mcg hypericin) for 10 days.<sup>1</sup> Concurrent use of higher doses of hypericum (4 g) with digoxin for 10 days was associated with a signficiant 25% and 19% reductions in average digoxin AUC and minimum serum concentration (Cmin), respectively, in a study of healthy volunteers.<sup>2</sup> In contrast, a study in 28 healthy volunteers concluded that lower-concentration hypericum products did not significantly change (i.e., less than 12% change) digoxin pharmacokinetic parameters.<sup>3</sup> Hypericin is one of the primary chemical entities in St Johns Wort. The precise clinical significance of this interaction is unknown, but such changes in AUC could be sufficient to cause problems in some patients. The effect of hypericin on digitoxin in unknown. <br><br>The mechanism of this apparent interaction is likely related to the ability of hypericin (and/or other compounds in St Johns Wort) to induce the p-glycoprotein-mediated efflux of digoxin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Johne A, Brockmoller J, Bauer S, et al, “Pharmacokinetic Interaction of Digoxin With an Herbal Extract From St John’s Wort (Hypericum Perforatum),” <i>Clin Pharmacol Ther</i>, 1999, 66:338-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10546917\">[PubMed 10546917]</a></p>\n<p>2. Mueller SC, Uehleke B, Woehling H, et al, “Effect of St John's Wort Dose and Preparations on the Pharmacokinetics of Digoxin,” <i>Clin Pharmacol Ther</i>, 2004, 75(6):546-57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15179409\">[PubMed 15179409]</a></p>\n<p>3. Arold G, Donath F, Maurer A, et al, “No Relevant Interaction with Alprazolam, Caffeine, Tolbutamide, and Digoxin by Treatment with a Low-Hyperforin St John's Wort Extract,” <i>Planta Med</i>, 2005, 71(4):331-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15856409\">[PubMed 15856409]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7882":"<p><b>Title</b> Estazolam / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Macrolide Antibiotics may increase the serum concentration of Estazolam. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider using an alternative agent that is less likely to interact. Azithromycin is likely a lower-risk macrolide, and benzodiazepines less dependent on CYP3A-mediated metabolism (e.g., lorazepam, oxazepam, temazepam) are similarly less likely to interact. If estazolam must be used together with a CYP3A-inhibiting macrolide, use extra caution and closer monitoring for excessive estazolam effects. Reduced estazolam doses may be necessary.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Clarithromycin, Erythromycin (Systemic), Telithromycin<br><b>Exceptions</b> Azithromycin (Systemic), Fidaxomicin, Roxithromycin, Spiramycin</p>\n</div> \n<p><b>Discussion</b> Macrolide antibiotics increase serum concentrations of benzodiazepines to varying degrees. According to estazolam prescribing information, concurrent use with very strong CYP3A inhibitors, such as ketoconazole or itraconazole is contraindicated due to the risk for impaired estazolam metabolism, and concurrent use of estazolam with other significant, though less potent inhibitors of CYP3A, such as erythromycin, should be performed with caution.<sup>1</sup> Though specific data with estazolam and macrolides are not available, data with the similar benzodiazepines triazolam and midazolam confirm this potential for at least the CYP3A-inhibiting macrolides to interact with such benzodiazepines to a clinically significant degree.<br><br>The mechanism of such an interaction appears to be related to macrolide inhibition of CYP3A-mediated metabolism of estazolam.<sup>2</sup> As such, benzodiazepines that do not rely exclusively on CYP3A (e.g., lorazepam, oxazepam, and temazepam) and/or macrolides that are less potent inhibitors of CYP3A (e.g., azithromycin) would likely be safer alternatives.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Estazolam. Corona, CA: Watson Pharma, Inc., September 2008.</p>\n<p>2. Miura M, Otani K, Ohkubo T. Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. <i>Xenobiotica</i>. 2005;35(5):455-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16012077\">[PubMed 16012077]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7883":"<p><b>Title</b> Midazolam / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Macrolide Antibiotics may increase the serum concentration of Midazolam. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider using an alternative agent that is less likely to interact. Azithromycin is likely a lower-risk macrolide, and benzodiazepines less dependent on CYP3A-mediated metabolism (e.g., lorazepam, oxazepam, temazepam) are similarly less likely to interact. The interaction with oral midazolam is expected to be of greater magnitude than that with intravenous midazolam. If midazolam must be used together with a CYP3A-inhibiting macrolide, use extra caution and closer monitoring for excessive midazolam effects. Appropriate monitoring and equipment/trained personnel for responding to excessive midazolam effects should be immediately available if this combination is used. Reduced midazolam doses may be necessary. Canadian labeling for clarithromycin states that the use of oral midazolam and clarithromycin is contraindicated.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Clarithromycin, Erythromycin (Systemic), Telithromycin<br><b>Exceptions</b> Azithromycin (Systemic), Fidaxomicin, Roxithromycin, Spiramycin</p>\n</div> \n<p><b>Discussion</b> Concurrent use of oral midazolam with clarithromycin, erythromycin, or telithromycin has been associated with a 3.6- to 8-fold increase in midazolam AUC,<sup>1,2,3,4,5,6,7</sup> while use of intravenous midazolam with these macrolides was associated with a 2- to 3.2-fold increase in midazolam AUC.<sup>4,5,6</sup> A significant increase in the pharmacodynamic effect of midazolam was also noted in several interaction studies.<sup>1,2,3,5,6,7,8</sup> Published case reports also describe significantly enhanced midazolam effects associated with concurrent use of erythromycin in both pediatric and adult patients.<sup>9,10,11</sup><br><br>Of note, several studies examining the interaction between midazolam and azithromycin have reported no significant interaction, including both pharmacokinetic and pharmacodynamic outcomes.<sup>1,3,7,12,13</sup><br><br>The mechanism of interaction interaction appears to be related to macrolide inhibition of the CYP3A-mediated metabolism of midazolam in both the intestines and the liver. Consistent with this, several studies have shown that clarithromycin and erythromycin significantly inhibit the systemic clearance of midazolam (by 54-85%).<sup>2,4,14</sup> It is the combined inhibition of intestinal and hepatic CYP3A that seems to account for the higher magnitude interaction with oral versus intravenous midazolam.<sup>14</sup> As such, benzodiazepines that do not rely exclusively on CYP3A (e.g., lorazepam, oxazepam, and temazepam) or do not undergo significant first-pass metabolism, and/or macrolides that are less potent inhibitors of CYP3A (e.g., azithromycin) would likely be safer alternatives.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zimmermann T, Yeates RA, Laufen H, et al. Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. <i>Arzneimittelforschung</i>. 1996;46(2):213-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8720318\">[PubMed 8720318]</a></p>\n<p>2. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. <i>Clin Pharmacol Ther</i>. 1993;53(3):298-305. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8453848\">[PubMed 8453848]</a></p>\n<p>3. Yeates RA, Laufen H, Zimmermann T. Interaction between midazolam and clarithromycin: comparison with azithromycin. <i>Int J Clin Pharmacol Ther</i>. 1996;34(9):400-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8880291\">[PubMed 8880291]</a></p>\n<p>4. Quinney SK, Haehner BD, Rhoades MB, et al. Interaction between midazolam and clarithromycin in the elderly. <i>Br J Clin Pharmacol</i>. 2008;65(1):98-109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17635500\">[PubMed 17635500]</a></p>\n<p>5. Prescribing information. Biaxin XL (clarithromycin). North Chicago, IL: AbbVie Inc., August 2013.</p>\n<p>6. Prescribing information. Ketek (telithromycin). Bridgewater, NJ: sanofi-aventis U.S. LLC, 12/2010.</p>\n<p>7. Prescribing information. Midazolam syrup. Columbus, OH: Roxane Laboratories, Inc., September 2012.</p>\n<p>8. Mattila MJ, Idanpaan-Heikkila JJ, Tornwall M, Vanakoski J. Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. <i>Pharmacol Toxicol</i>. 1993;73(3):180-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8265524\">[PubMed 8265524]</a></p>\n<p>9. Hiller A, Olkkola KT, Isohanni P, Saarnivaara L. Unconsciousness associated with midazolam and erythromycin. <i>Br J Anaesth</i>. 1990;65(6):826-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2265054\">[PubMed 2265054]</a></p>\n<p>10. Senthilkumaran S, Subramanian PT. Prolonged sedation related to erythromycin and midazolam interaction: a word of caution. <i>Indian Pediatr</i>. 2011;48(11):909. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22711153\">[PubMed 22711153]</a></p>\n<p>11. Bobade S, Kulkarni V, Dhumne S, et al. Drug interaction leading to prolonged sedation in a postoperative high risk coronary bypass surgery patient. <i>Indian J Crit Care Med</i>. 2011;15(1):55-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21633550\">[PubMed 21633550]</a></p>\n<p>12. Mattila MJ, Vanakoski J, Idanpaan-Heikkila JJ. Azithromycin does not alter the effects of oral midazolam on human performance. <i>Eur J Clin Pharmacol</i>. 1994;47(1):49-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7988623\">[PubMed 7988623]</a></p>\n<p>13. Backman JT, Olkkola KT, Neuvonen PJ. Azithromycin does not increase plasma concentrations of oral midazolam. <i>Int J Clin Pharmacol Ther</i>. 1995;33(6):356-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7582388\">[PubMed 7582388]</a></p>\n<p>14. Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. <i>Clin Pharmacol Ther</i>. 1998;64(2):133-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9728893\">[PubMed 9728893]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7884":"<p><b>Title</b> Warfarin / Bee Pollen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bee Pollen may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased anticoagulant effects of warfarin (i.e., increased International Normalized-Ration (INR), signs/symptoms of bleeding, etc.) if bee pollen is initiated or if dose/product is changed. Warfarin dose reduction may be warranted.</p> \n<p><b>Discussion</b> In a case report, a 71-year-old male taking warfarin was found to have an International Normalized-Ratio (INR) of 7.1 (goal = 2 to 3) during a routine checkup.<sup>1</sup> His past medical history is significant of atrial flutter, hypertension, hyperlipidemia, diabetes mellitus, erectile dysfunction, obesity, and hypothyroidism. His medication use at the time of the checkup included warfarin, hydrochlorothiazide, lisinopril, levothyroxine, simvastatin, glyburide, metformin, vardenafil, aspirin, a multivitamin, and his herbal products included Cataplex E2, Cataplex B, and Cyruta. All of the aforementioned medications and herbal supplements had been consistently used within the previous 9 months, during which time the patient's INR ranged from 1.9 to 3.3. The only addition or change to his medication use was that the patient initiated the use of bee pollen granules (1 teaspoon twice daily). This was initiated about 1 month prior to checkup for perceived general health benefit. The patient denies use of alcohol or tobacco or changes in vitamin K consumption, missing or using extra warfarin, acute illness, or diarrhea. The patient’s warfarin was held for 3 days and his INR was rechecked and found to be 3.7 so it was held for an additional day then restarted at an 11% decreased total weekly dose.<br><br>The exact mechanism for this reported interaction is unknown, but the authors of this case report suggest that it may be due to the CYP2C9 inhibition caused by the flavonoids within the bee pollen.<sup>1</sup> Warfarin’s most active form (S-warfarin) is metabolized primarily by CYP2C9 and its concentration may be altered by changes to CYP2C9. While some of the flavonoids reported to be found in bee pollen have been found to inhibit CYP2C9 in vitro, but it is unlikely that taking labeled doses of bee pollen would deliver enough of these flavonoids to achieve a clinically significant degree of CYP2C9 inhibition, though limited data about the pharmacokinetics of many of the individual flavvonoids are available.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hurren KM, Lewis CL. Probable interaction between warfarin and bee pollen. <i>Am J Health Syst Pharm</i>. 2010;67(23):2034-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21098375\">[PubMed 21098375]</a></p>\n<p>2. Si D, Wang Y, Zhou Y, et al. Mechanism of CYP2C9 inhibition by flavones and flavonols. <i>Drug Metab Dispos</i>. 2009;27:629-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19074529\">[PubMed 19074529]</a></p>\n<p>3. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. <i>Am J Clin Nutr</i>. 2005;81(1 Suppl):230S-42S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15640486\">[PubMed 15640486]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7885":"<p><b>Title</b> Abiraterone Acetate / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Abiraterone Acetate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of abiraterone acetate with any strong CYP3A4 inducer. If such a combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during concomitant use.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in the abiraterone acetate U.S. prescribing information, coadministration of rifampin (600 mg daily for 6 days) decreased the AUC of abiraterone by 55% following a single 1 g dose of abiraterone acetate.<sup>1</sup> One case report describes a 65-year-old man whose abiraterone AUC was reduced by 67% following one month of treatment with the strong CYP3A4 inducer carbamazepine.<sup>2</sup> The patient had metastatic, castration-resistant prostate cancer and was treated with abiraterone acetate and prednisolone prior to being started on carbamazepine (200 mg twice daily) for facial neuropathy. Abiraterone concentrations normalized following carbamazepine discontinuation.<br><br>The suspected primary mechanism of this interaction is induction of the CYP3A4-mediated metabolism of abiraterone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zytiga (abiraterone acetate) [prescribing information]. Horsham, PA: Janssen Biotech Inc; May 2016.</p>\n<p>2. Benoist GE, van der Doelen MJ, Ter Heine R, van Erp NP, Mehra N. A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer. <i>Br J Clin Pharmacol</i>. 2018; Jan 31 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29384591\">[PubMed 29384591]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}